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Isolation and Identification of the O-linked-β-N-aetylglucosamine (O-GlcNAc) Modified
Proteins in the Developing Oocytes of Xenopus laevis
Sreelatha Paspuleti
ABSTRACT
Oocyte development in Xenopus laevis spans six morphologically distinct stages
(stage I-VI), and is associated with a decrease in protein O-GlcNAc levels. As a first step
in elucidating the role of O-GlcNAc in developing oocytes, initial efforts were focused on
isolation and identification of fifteen modified proteins that decrease during oocyte
development. Stage I oocytes due to their high amounts of these proteins, were used as
starting material for purification. Multiple affinity and specific antibody based purification technique were initially used in an attempt to enrich the O-GlcNAc proteins. Due to
the unique properties of the proteins ultimately identified, these techniques were unable
to provide sufficient material for sequencing. However, differential centrifugation
coupled with 2D-gel electrophoresis was highly successful. The majority of isolated
proteins were strongly basic in nature with pIs 8-10. Coomassie stained bands from 2Danalysis were trypsin digested, and peptides were sequenced by mass spectroscopy
(Finnigan LCQ). Mass data were interpreted by Bioworks software, and protein
sequences were compared to multiple protein databases. Initially, six proteins were
identified as Thesaurin a (42Sp50), cytoplasmic mRNA binding protein p54, y-box
homolog, Xp 54 (ATP dependent RNA helicase p54), Vg1 RNA binding protein variant A,
vi

Zygote arrest 1(Zar1) and Poly (A) binding protein (PABP). Thesaurin a, the main
component of 42S particle of previtellogenic oocytes (stages I-III) is involved in tRNA
storage and possess low tRNA transfer activity; y-box factor homolog and Xp54 are
present in oocyte mRNA storage ribonucleoprotein particles; Vg1 RBP variant A
associates mVg1 RNA to microtubules in order to translocate to the vegetal cortex; Zar1
is involved in oocyte-to-embryo transition; and PABP initiates mRNA translation. This
study is the first to characterize these oocyte specific proteins as O-GlcNAc modified
proteins. Overall, the presence of several O-GlcNAc proteins in oocytes, the reduction in
their levels/ O-GlcNAc levels, and the variation in maturation time in the presence of
HBP-flux modulators in developing oocyte indicates O-GlcNAc may play important roles
in metabolism, cell growth and cell division of X. laevis oocytes. Therefore, identifying
the remainder of these proteins and elucidating the O-GlcNAc role in their function is a
worthwhile pursuit.

vii

Chapter 1
Introduction
1. The use of Xenopus laevis oocyte as a model system for the cell developmental
studies involving O-GlcNAc modified proteins:
1.1 Statement of the Problem
O-linked-β-N-Acetylglucosamine (O-GlcNAc) modification characterized two
decades ago [1] has been found to be ubiquitous in metazoans and is a dynamic posttranslational modification of many nuclear and cytosolic proteins. Subsequent studies
have found the modification on a wide variety of proteins suggesting the diversity in funtions of this modification [2]. Importantly, the levels of O-GlcNAc in different types of
cells changes in response to the external stimuli, such stress [3], insulin signaling [4],
glucose metabolism [5-7], and cell cycle progression [7] suggesting a potential regulatory
role for O-GlcNAc modified proteins in many cellular processes. Additionally, changes
in O-GlcNAc have been linked to diseases such as Alzheimer’s [5], diabetes [8], and
cancer [9] highlighting its potential clinical importance.
As one approach to investigating the possible function of O-GlcNAc in cell
growth and division, oocytes from the South African clawed frog, Xenopus laevis were
selected as a model system. This oocyte system has long been used as a general model for
the study of growth and differentiation as well as analysis of cell cycle processes in eukaryotes [10]. Interestingly, recent reports have demonstrated that changes of O-GlcNAc
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levels in oocytes impact the oocyte growth and maturation [11-13], although the exact
function of the modification and the role of modified proteins are still unclear.
For instance, the toxic effect of the galactosyl capping of O-GlcNAc residues
observed in maturing Xenopus laevis oocyte has suggested the possible role of the OGlcNAc in the aster formation during meiosis [12]. A delayed progesterone stimulated
maturation of the fully grown oocytes when incubated with compounds which elevate OGlcNAc levels, and a reduction in O-GlcNAc levels of developing oocyte during the
stage progression (stage I-VI) have indicated that one or more O-GlcNAc modified proteins may be critical for oocyte maturation and development [11,13].
In addition, the decrease in O-GlcNAc levels during the stage progression [11]
(stage I-VI) is in correlation to the increase in O-GlcNAc removal activity of OGlcNAcase. The reduction in levels that occurs especially in high molecular weight protein (> 36 kDa) reflects the metabolic transition from glycolytic to gluconeogenic state
[11]. A similar phenomenon of O-GlcNAc levels was observed during the transition of
cell to malignancy, indicating the fully grown oocyte (stage VI) has at least some characteristics in common with a malignant cell where the regulation of the modification is also
altered [11].
All these experimental findings suggest that the O-GlcNAc modification might
play some important regulatory role in connecting cell growth, division and metabolism.
As one step in elucidating these connections in a developmental system, it is important to
first isolate and identify the modified oocyte proteins that change during oocyte development. Since a relatively large fraction of stage I oocyte proteins are O-GlcNAc
modified, these oocytes were used as source for the studies described herein [11].
2

1.2 Introduction to Xenopus laevis oocyte
The oocyte of Xenopus laevis, the South African Clawed frog (Figure 1.2.1.1) is a
good model system for biochemical studies for several reasons. First of these is the availability of abundant literature on its anatomy, morphology and metabolism [10]. Second,
the frogs being highly adaptable and resistant to infection can be easily maintained at low
cost in the laboratory. Third, because of continuous and asynchronous oogenesis, the
oocytes in all stages of development can be obtained from the ovary of an adult female
frog. The ovarian tissue regenerates in two to three months and oocyte can be harvested
up to four times from each frog [13]. Finally, in particular, the stage VI oocyte due to its
large sizes can be used with ease for semi-quantitative microinjection studies that have
proven instrumental in understanding the control of cell proliferation and the regulation
of cell cycle [15, 16].
1.2.1 Oogenesis
Oogenesis is defined as the process of formation of ova or unfertilized eggs from
the oogonia. The process is comprised of two phases, the first phase is a growth phase
and second phase is a maturation phase. The oogonia enter meiosis I and become arrested at prophase I, where they are termed oocytes. At the prophase I arrest, the oocytes
begins accumulating a large store of mRNA, mitochondrial DNA, and proteins required
for the initial rapid cell divisions, along with a large amounts of yolk proteins and glycogen also required for post-fertilization. This first phase is further sub-divided into six
major stages based on the morphology and anatomy of the growing oocyte [17] (Figure
I.2.2.1). During this stage progression, the oocyte transforms from a small and transparent stage I to large and banded stage VI oocyte that are described stage-wise in
3

Figure 1.2.1- Female Xenopus laevis (South African Clawed Frog) Female frogs
larger than males. An average frog weighs approximately 130-150 g and capable
regenerating the ovarian tissue in three-four weeks. They are maintained in tanks
containing room temperature dechlorinated water and approximately 1 liter of water per
frog). They are fed twice to thrice a week with the nutrient rich frog brittle. (Nasco)
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Figure 1.2.2.1- The different stages of Xenopus laevis oocytes during oogenesis. Two
phases of the oogenesis (formation of egg for fertilization) are displayed. The first phase
constitutes the oocyte growth, and further sub-divided into six major stages (I-VI) based
on the features such as, diameter, pigmentation color and the amount of yolk protein in
the cytoplasm. The second phase is maturation of fully grown oocyte (stage VI) where
the oocyte undergoes germinal vesicle breakdown (GVBD) on progesterone stimulation.
Figure from the website: http://www.luc.edu/depts/biology/dev/xenoogen.htm.

Stage

Stage progression of oocyte

Maturing oocyte

Stage I oocytes- clear and transparent (50-300 µm)
Stage II oocytes- white and opaque (300-450 µm)
Stage III oocytes- lightly pigmented all over (450-600 µm)
Stage IV oocytes- yolk protein deposition at the upper animal hemisphere (600-1000 µm)
Stage V oocytes- accumulating yolk and have darker pigmented color (1000-1100 µm)
Stage VI oocytes- fully grown and have progesterone receptors on their plasma
membrane (1100-1300 µm)
Stage VI oocytes undergo meiosis when exposed to the steroid progesterone producing a
white spot at the animal pole.
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detail in the following section 1.2.3.
In the maturation phase, the fully grown oocyte (stage VI) forms an unfertilized
egg upon stimulation with the steroid hormone, progesterone [18]. The stimulated oocyte
arrested at the G2/M border resumes meiosis I, and progresses through meiosis II to become once again arrested at metaphase II. A white spot, the attachment of meiotic spindle
to plasma membrane was formed on the animal hemisphere of stage VI oocyte indicating
the breakdown of the oocyte nucleus or germinal vesicle (GVBD) [19]. The formation of
white spot on the animal hemisphere is the most obvious external indication of oocyte
maturation (Figure 1.2.1.1). Thus the stimulated oocyte undergoes a number of morphological and biochemical changes prior to arrest at the metaphase II. The result of maturation process is a matured oocyte or unfertilized egg that is now ready for fertilization.
1.2.2 Oocyte Development
As found in the frog ovary, oocytes are arrested at prophase I between the second
growth phase (G2) and the mitotic phases (M). They undergo a significant change from a
small transparent oocyte at stage I to a large banded oocyte by stage VI with a distinct
brown hemisphere or so called animal pole and green vegetal hemisphere or vegetal pole
[17]. The nucleus and majority of the metabolic functional organelles are found in approximately 0.5 µl of the animal hemisphere while the equal sized vetegal hemisphere
contains mainly yolk protein and glycogen in stages IV-VI (Figure 1.2.2.1). The small
stage I oocytes range from 50 to 300 µm in diameter with a transparent cytoplasm and
visible germinal vesicle (nucleus). The clear cytoplasm contains a microscopic yellowish
mitochondrial mass and stains intensely for RNA and lightly for polysaccharides. These
oocytes are previtellogenic, which means they are not involved in active accumulation of
6

the yolk proteins. In the ovary, the interspersed oocytes from all stages of development
are surrounded by three layers; the innermost follicular epithelium, the middle theca
made up of connective tissue containing blood vessels and fibroblasts, and the outermost
surface epithelium [17].
The white and opaque stage II oocytes are 300-450 µm in diameter, and comprises of 45% of the Stage II to VI oocyte population. At this stage, the acellular vitelline
envelope begins to develop. At Stage III, the visible pigmentation and the vitellogenesis
(the process of active accumulation of the yolk proteins) are initiated. These oocytes are
tan or light brown in color but with no visible differentiation of the animal and vegetal
poles. They range from 450-600 µm in diameter and RNA synthesis peaks at this stage.
The stage IV oocytes range in size from 600-1000 µm. They show the clear differenttiation of the animal and vegetal poles. The animal pole is dark brown in color containing the nucleus. Stage V grow from 1000-1200 µm in diameter and develops a distinct
boundary between the dark brown animal and the greenish yellow vegetal hemispheres
[17].
Stage VI oocytes are post vitellogenic. The two distinct brown animal and light
greenish yellow vegetal hemispheres separated by an unpigmented 0.2 mm wide equatorial band. The nucleus is eccentrically situated near the animal pole, and a clear polarization of nuclear envelope becomes visible [17]. The fully grown oocyte is 1,000,000
times the volume of typical somatic cell [10]. Half of the volume consists of the yolk proteins while the nucleus is now 300-400 nm in diameter [10]. These oocytes at the G2/M
border arrest are responsive to the hormone, progesterone and upon stimulation undergo
germinal vesicle breakdown (GVBD) into an unfertilized egg.
7

1.2.3 Protein synthesis during oogenesis
The Xenopus oocytes arrested at prophase I have accumulated massive amounts
of yolk proteins, lipids and maternal mRNA required for the series of cell divisions that
take place during maturation, fertilization and embryogenesis. Therefore a fully grown
oocyte (stage VI) as described above is an abnormally large cell with a bloated nucleus
referred to as the germinal vesicle. The contents of this unusual cell are summarized in
the table 1.5.1 [20]. Table 1.5.1 shows that the oocyte at stage VI consists of largest
amounts of yolk protein, ribosomal protein mRNA, mitochondrial DNA and rGTP (precursors). Whereas non-yolk proteins, heat shock 70 mRNA, oocyte chromosomal DNA,
and dTTP (precursors) were present in lowest amounts. The accumulation of mRNA is
completed by the end of stage II of oogenesis. However, the lampbrush chromosomes
that exhibit transcription rates higher than those typical for somatic cells remains active
during the entire period of oogenesis [21-23]. The estimated rate of poly (A) mRNA
entry into cytoplasm in stage III and VI oocytes is approximately 1.4 ng per day. Even
though, this is a small percentage of the total maternal mRNA, the actual amount of
message that enters the cytoplasm is quite high due to the enormous rate of nuclear RNA
synthesis [23]. The DNA microinjection experiments show that maternal transcripts are
responsible for most of the protein synthesis during oogenesis, not the DNA injected into
the oocyte nucleus [24].
The non-yolk proteins are accumulated in the oocytes by endogenous protein
synthesis and yolk deposition by micropinocytosis of vitellogenin synthesized by the
adult frog in the liver [25, 26]. The rate of protein synthesis increases over 100-fold during the stage progression from stage І-VI. A similar increasing trend was observed in the
8

Table 1.2.3.1- Composition of a Xenopus oocyte, full grown and without follicles
cells.
(Total Volume, 1 µl; yolk-free volume 0.5 µl; GV volume 40 nl)

Component

Weight

Number of components

% of total in
cytoplasm

DNA
Oocyte chromosomal
Nucleolar (rDNA)
Mitochondrial

12 pg
25 pg
4000 pg

2 x 106 rDNA repeats
~108 gemones

None
None
100%

RNA
Ribosomal protein m-RNA
5S
tRNA
snRNA U1
polyA+RNA
Ribosomal protein m-RNA
Actin mRNA
Heat-shock 70m RNA

5 µg
60 ng
60 ng
0.07 ng
80 ng
10 ng
~1 ng
0.004 ng

1012 ribosomes
1012
1.5 x 1012
8 x 108
5 x 1010 (if 2500 bases long)
2 x 1010
5 x 108
106

-

250 µg
25 µg
140 ng
250 ng

5 x 1014 ( 30 K protein)
5 x 1012
5 x 1012
~ 105 x somatic cell
5 x 105 x somatic cell

100%
90%
50%
98%
-

10 pmol
250 pmol
40 pmol

-

-

Protein
Yolk
Non-yolk
Histones
Nucleoplasmin
RNA polymerase I and II
RNA polymerase III
Precursors
dTTP
rGTP
Methionine

99%
99%
99%
99%
90%

This table is from ‘Microinjection and Organelle Transplantation Techniques. Methods
and Applications’. Edited by Celis J. E; Graessmann A; Loyter, A. (1986)
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amount of ribosomal RNA, and approximately 2% of the ribosomal RNA was found to
be engaged in protein synthesis during oogenesis [27]. An additional two fold increase is
observed when maturation is induced in the oocyte [28]. Gurdon et al. have demonstrated
that the stage VI oocytes have spare translational capacity, that is injected mRNAs are
translated in addition to endogenous messages [29]. However, the latter studies have
shown that the translational capacity of the oocyte is not uniform for different classes of
messages. The injected messages that are translated on the free cytosolic polysomes were
expressed, whereas the ones that are translated on the endoplasmic reticulum resulted in
the accumulation of these injected mRNA [30]. This non-uniformity in the translation of
mRNAs was apparently due to the limited availability of one of the translational machinery, the ribosomes on endoplasmic reticulum in the oocyte [31].
1.2.4 Gluconeogenic metabolism
In addition to the accumulation of yolk protein, the developing oocyte synthesizes
a large amount of glycogen that is used as the source of energy during embryogenesis
(from gastrulation stage onwards) [32]. Incorporation of microinjected 32P-labelled glycolytic intermediates, such as 32P-labeled phosphoenolpyruvate and glucose-6-phosphate
into UDP-glucose and then presumably into glycogen in the stage VI oocytes, fertilized
eggs, and cells of cleaving embryos has suggested that basic metabolism in these cells is
gluconeogenic and glycogenic until the embryo reaches the late blastula stage [33]. Interestingly, rapid incorporation of 32P-glucose-6-phosphate into ATP, inorganic phosphate and creatine phosphate in stage II oocytes and not in stage VI oocytes also indicated a
metabolic transition from glycolytic to gluconeogenic state [33]. Since enolase is thought
to out-compete pyruvate kinase for any phosphopyruvate, and the activity of the fructose
10

1, 6-bisphosphate is low in the stage II and VI oocytes [33], the inorganic 32P is found in
very low amounts compared to typical cells. This indicates that the oocyte metabolism is
mainly gluconeogenic, and very little energy is derived from glycolysis. However, the
(U-14C)glucose microinjection into the oocytes Stage VI) of Caudiverbera caudiverbera,
the Chilean frog, and Xenopus laevis (data not shown) has demonstrated glycogen synthesis by an indirect pathway involving glycolytic breakdown of glucose to lactate, which
is then converted into glycogen via an apparently connected gluconeogenic pathway [34].
Therefore glycogen synthesis might be possible in both direct and indirect pathways in
amphibian oocytes.
Since there is no glycogen breakdown until the gastrulation, the amino acids especially glutamine are used as the carbon source for cellular energetics and macromolecular synthesis in the fertilized egg and in the oocytes [33]. A similar type of metabolism
where glutamate is a major energy source has also been observed in some tumor cells
[35, 33] might explain some of the decreases in O-GlcNAc levels in these cells [36].
1.3 Introduction to O-linked-β-N-acetylglucosamine modification
The glycosidic linkage of the β-N-acetylglucosamine through the hydroxyl side
chains of serine or threonine residues of proteins is termed as the O-linked-β-N-acetylglucosamine (O-GlcNAc) modification (Figure 1.3.1). The modification occurs in many
nuclear and cytosolic proteins of metazoans [1, 37]. This novel post-translational modification was first discovered in murine lymphocytes by Torres and Hart in 1984. Since the
first characterization, a myriad of proteins have been found to bear this modification [2]
(Table1.2.1). Most of these O-GlcNAc modified proteins are also phosphoproteins. In an
analogous manner to O-phosphorylation, the modification is regulated by a unique set of
11

proteins that add and remove the modification in response to cellular stimuli [7]. Given
the dynamic nature of O-GlcNAc modification, and the fact that in at least in some cases
it acts as an alternative to protein phosphorylation, this modification has increased the
complexity of the regulatory processes in the cell [2, 9, 38-41].
The O-GlcNAc modification is added to protein by a ubiquitous enzyme, uridine
diphospho-N-acetylglucosamine: polypeptide β-N-acetylglucosminyl transferase or OGlcNAc transferase (OGT). The OGT gene that is present on the X chromosome was
shown to be essential for cell viability [42]. OGT is a soluble protein found in the cytosol
but more predominantly in nucleus was first characterized in rat liver extract by the Hart
group [43]. The enzyme composed of three subunits in an α2β conformation with two 110
kDa α-subunits and one 78 kDa β-subunit [44]. The UDP-GlcNAc level in the cell regulates the enzyme activity of the α-subunit with a low apparent Km 545 nM for UDPGlcNAc that can change with the concentration of UDP-GlcNAc and the other regulators
[45]. OGT contains an N-terminal tetratricopeptide repeat (TPR) domain and C-terminal
catalytic domain [46, 47]. The C-terminal domain that resembles glycogen phosphorylase
superfamily of glycosyl transferase hypothesized to contain two Rossman type folds and
UDP-GlcNAc binding site [47]. Whereas, the N-terminal TPR domain mediates proteinprotein interaction that appears to be necessary for the enzyme self-association, as well as
the substrate recognition [48-52]. The crystal structure of human OGT has shown that
homodimeric TPR domain containing 11.5 TPR repeats form an elongated superhelix,
and its concave surface is lined by a conserved array of asparagines. This asparagines array shows marked similarity to the array in armadillo (ARM) repeat proteins, importin α
and β-catenin, and thus suggesting that the TPR domain of OGT uses a similar mecha12

Figure 1.3.1- O-linked β-N-acetylglucosamine (O-GlcNAc) modified protein.
N-acetylglucosamine group in β-linkage at the hydroxyl group of the serine, Ser residue
of the protein.
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Table 1.3.1- List of the O-GlcNAc modified proteins classified based on their
functions. Table from the review ‘Proteomic Approaches to Analyze the Dynamic
Relationships between Nucleocytoplasmic Protein Glycosylation and
Phosphorylation’ by Whelan, Stephen A.; Hart, Gerald W. (Circulation research,
(2003), 93, 1047-58).

Functional Subgroup

Protein

Reference from the above review
paper

Chaperones

Heat shock protein 27 (HSP27)
Heat shock cognate 70 (HSC70)
Heat shock protein 70 (HSP70)
Heat shock protein 90 (HSP90)

90, 102
96*
104
96*

Chromatin

Chromatin associated proteins

105

Actin-based

Ankyrin G
Cofilin
E-cadherin
Myosin
Protein band 4.1
Synapsin
Talin

106
96*
107*
108*
109
110
111

Intermediate Filaments

Keritins 8, 13, 18
Neurofilaments H, M, L

112, 113
114, 115

Microtuble-based

α-tubulin
Dynein LC1
Microtubule associated proteins 2 & 4
(MAP 2 & 4)
Tau

104*
96*

Adenovirus type 2 & 5 fiber proteins
Assembly protein 3 & 180 (AP-3 & AP-180)
β-Amyloid precursor protein (β-APP)
β-Synuclein
Piccolo
Plakoglobin

117, 118
119, 120
23
121
96*
122

Casein Kinase II (CKII)
Glycogen synthase kinase-3β (GSK-3β)
Insulin receptor substrate 1 & 2 (IRS-1 & -2)

63
63
27, 28,
67
28

Cytoskeleton

Other

Kinases and Adaptor Proteins

PI3-kinase (p85)
Metabolic Enzymes

Enolase
Endothelial nitric oxide synthase (eNOS)
Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH)

14

116
16

96*
72
96*

Glycogen synthase (GS)
Phosphoglycerate kinase (PGK)
Pyruvate kinase (PK)
UDP-glucose pyrophosphrylase (UGP)

70
96*
96*
96*

Estrogen receptor-α & β (ER-α & -β)

17, 123,

V-erbA

125*

Nup 62
Nup 153, 214, 358
Nup 180
Nup 54, 155

126
127
128
96*

Phosphatases

Nuclear tyrosine phosphatase p65
Phosphatase-2a inhibitor (i2pp2a)

129
96*

Polymerases

RNA Pol II

15

ProtO-oncogenes

c-Myc

14

RNA binding proteins

40S ribosomal protein S24 (40SrpS24)
Elongation factor 1-α (EF-1)
Eukaryotic initiation factor 4A1 (EIF 4A1)
Ewing-sarcoma RNA-binding protein (EWS)
RNA binding protein G (hnRNP G; La-antigen)

96*
96*
96*
96, 130
131

Transcription factors

AP-1 (c-fos and c-jun)
β-catenin
CAAT box transcription factor (CTF, NF-1)

132*
107
132*

Nuclear Hormone Receptors
124
Nuclear Pore Proteins

(NUP)

Cyclic AMP response element-binding protein
(CREB)
ELF-1 (Ets transcription factor)
Enhancer factor 2D (EF-2D)
Hepatocyte Nuclear Factor 1 (HNF-1)
KIAA0144, Oct1
NF-κB
OGT interacting protein 106 (OIP-106)
p53
Pancreatic/duodenal homeobox-1 protein
(PDX-1, IPF-1, STF-1)
PAX-6
Pancrease-specific transcription factor (PTF-1)
Human C1 transcription factor (HCF)
Serum Response Factor (SRF)
Sp1
Ying Yang 1 (YY1)
Tumor suppressors
unpublished

Retinoblastoma protein (Rb)

Viral Proteins

Baculovirus gp41 tegument protein
HCMV UL32 (BPP) tegument protein
NS26 Rotavirus Protein

15

95
26
96*
133
96*
134
38
135
136
137
138*
96*
91
132
139

140
141
142

SV-40 large T-antigen
unpublished
Virion basic phosphoprotein

143

Other

Annexin 1
96*
Collapsin response mediator protein-2 (CRMP-2)
121
Elongation initiation factor-2 associated
67 kDa (EIF2α p67)
144
Gaba-receptor interacting protein-1 (GRIF-1)
& Splice variants
38
Glut-1 & 4
145
Nucleophosmin
96*
Peptidyl prolylisomerase (PPI)
96*
Proteosome component C2
96*
O-GlcNAc transferase (OGT)
29
Q04323, UCH homolog
96*
Sec23, human homolog (hhSec23)
96*
Ran
96*
Rho GDP-dissociation inhibitor 1 (RhO-GDI α)
96*
Ubiquitin carboxy hydrolase (UCH)
121
*These identifications are still considered putative as supporting structural work has not been published.

nism of protein-protein interaction [52]. A group of proteins known as O-GlcNAc
interacting proteins (OIP) exists that mediate the interactions between the tetratricopeptide repeats of enzyme and the substrates [53].
Even though, OGT is found in all tissues examined, the levels of expression differ
among tissues. In addition, the levels of expression are not correlated to the activity, implying that the enzyme is regulated post-translationally [43, 46]. For example, OGT is
modified by both tyrosine phosphorylation and O-GlcNAcylation [51], although the role
of these modifications on the localization and the activity of enzyme are unknown. At the
substrate level, both the Km and Vmax for a variety of substrates is altered by the UDPGlcNAc levels. The enzyme has apparent Km for UDP-GlcNAc ranges from 0.05 µM-4.8
mM in cell extracts. The UDP-GlcNAc levels are in turn depends on extracellular signals,
the state of nutrition, development and differentiation [51, 54-59]. OGT remains active
across the physiological range of UDP-GlcNAc in the absence of UDP, a potent inhibitor
(Ki 200 nM) [45, 60].
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The removal of O-GlcNAc group is accomplished by a specific enzyme, β-NAcetylglucosaminidase (O-GlcNAcase) with a neutral pH optimum that is predominantly
localized to the cytosol. The enzyme is characterized from both rat spleen and human
brain. The ubiquitous enzyme is abundantly found in the brain, placenta and pancreas
[61, 62]. O-GlcNAcase has molecular weight of 106 kDa, and exists as a αβ heterodimer
with a 54 kDa α-subunit and 51 kDa β-subunit. The enzyme is found in both cytoplasm
and nucleus. Unlike, the more general specificity of lysosomal hexoaminidases with acidic pH optima, the neutral enzyme is not inhibited by GalNAc or its analogs, and shows
no other glycosidase activity. In addition, the enzyme does not cross-react with the antibodies against the lysosomal hexoaminidases [61,62]. However, similar to lysosomal
hexoaminidases, O-GlcNAcase has a Km = 1.1 mM for a general glycosidase substrate
paranitrophenyl-GlcNAc [63]. In contrast, streptozotocin (STZ) a glucosamine nitrosourea specifically inhibits O-GlcNAcase and not other hexoaminidases [64]. Another
strong inhibitor of O-GlcNAcase is O-(2-acetamido-2-deoxy-D-glucopyranosylidene)
amino-N-phenylcarbamate (Ki =54 nM PUGNAc) [65, 66]. Interestingly, O-GlcNAcase
retains the enzymatic activity upon cleavage by caspase-3 releasing the regulatory domain from the catalytic moiety, indicating that removal of O-GlcNAc may play a role in cell
death process [63]. Many soluble nuclear and cytosolic proteins as shown in table 1.3.1
are the targets of OGT and O-GlcNAcase. Many of the proteins characterized so far, such
as Estrogen Receptor β (ERβ), tau, SV-40 large T antigen, c-Myc oncogene, eNOS, RNA
polymerase II and αβ-crystallin show that O-GlcNAc and O-phosphate groups compete
for the same site [67-72]. However, in some proteins, there is a synergistic interplay of OGlcNAc and O-phosphate [73], and in all likelihood an antagonist and/or even no connec17

Figure 1.3.2- Schematic diagram of the hexosamine biosynthetic pathway and the
dynamic processing of O-GlcNAc modification by O-GlcNAc transferase and OGlcNAcase. The diagram represents the substrates, enzymes and inhibitors of the
hexosamine biosynthetic pathway (HBP) and during the regulation of O-GlcNAc
modification.
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tive effect may well be formed as more proteins are analyzed.
The galactosyl capping studies using β-D-1-4-galactosyltransferase in Xenopus
maturing oocyte have demonstrated the deleterious effect of the blocking the addition and
removal of O-GlcNAc, thus suggesting this post-translational modification may play a
significant role in cellular regulation [12, 74]. However, structural changes may also have
played a role in these outcomes. In another study, the elevation of O-GlcNAc using
PUGNAc has shown no effect on the cell growth rate [65]. The contradicting results
might be due to the rapid turnover of the PUGNAc and the replacement of it every 48
hours. As mentioned earlier, the OGT deletion studies in ES cells, embryonic fibroblast
or tissue using Cre-lox technology [75] is lethal, suggesting that OGT is essential for life
at single cell level [42, 76]. Since the substrate specificity of OGT changes at different
concentrations of UDP-GlcNAc, the O-GlcNAc levels on key regulatory proteins, including OGT can be modulated by altering the extracellular glucose levels through the
hexosamine biosynthetic pathway (as shown in the Figure 1.3.3) [77-87]. The change in
O-GlcNAc levels to different signals based on its nutritional state modulating the overall
behavior of the cell suggests that O-GlcNAc is a nutritional sensor [41, 63, 82, 88, 89].
For instance, the glucose starvation and forskolin treatment led to decreased glycosylation and increased degradation of Sp1, transcription factor and synthetic peptide through the ATPases in 19S regulatory subunits [90]. Apart from being a nutritional sensor, OGlcNAc is also a stress sensor [91]. In many other parallel studies, an increase in the OGlcNAc levels due to increase in glucose flux into the cells is observed in response to the
stress such as heat shock, UV, hypoxia, reductive, oxidative and osmotic stress [3].
Interestingly, the rapid induction of heat shock proteins (HSP) such as HSP70 and HSP40
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with the increase in O-GlcNAc shows that O-GlcNAc mediates stress tolerance [3].
However, the studies on diabetes have associated hyperglycemia with the increased cell
death in several systems that might be due to the down-regulation of AKT activation [9294]. The paradox may be due to the differences in the sensitivities of tissues/ cells to
insulin, the dependence on AKT signaling or the basal cell death rate to that of induced
cell death rate [91].
1.4 Earlier findings of the studies on O-GlcNAc modification in oocytes of Xenopus
laevis
Recent reports have demonstrated that changes of O-GlcNAc levels in oocytes are
related to the oocyte growth and maturation [11, 95], the exact function of the modification and the role of the modified proteins are still unclear. Slawson et. al. demonstrated
delayed progesterone stimulated maturation of the fully grown oocyte when incubated
with compounds such as glucose, glucosamine and PUGNAc before progesterone stimulation [11]. Additionally, when the oocytes were incubated with the glutamine-fructose-6phosphate amino trasferase (GFAT) inhibitor, DON (6-diazonorbenzene) that reduces
UDP-GlcNAc synthesis, nullified the glucose effect on the maturation. While the total
cellular O-GlcNAc content apparently does not change during progesterone stimulation
[11], another study has showed an approximate 4.5-fold increase in the O-GlcNAc content, mainly on two cytoplasmic proteins, one of 97 kDa, identified as β-catenin and
another unidentified 66 kDa protein [13]. Microinjection of GlcNAc has delayed progesterone-induced maturation in Xenopus oocytes without any change in O-GlcNAc content
suggesting that the modification could regulate protein-protein interactions required for
the cell cycle kinetic [13]. Like Sp1 transcription factor, β-catenin is also stabilized by O20

GlcNAcylation [83, 13]. In addition, the microinjection of galactosyl transferase (GalT)
into the progesterone-stimulated oocyte was shown to be toxic [12]. This GalT toxicity
was reported due to the galactosyl capping of the O-GlcNAc residues that appear to disrupt aster formation during the meiosis or causes any other cellular effects. Thus, the OGlcNAc modification might be facilitating the protein–protein interactions necessary for
the maturation process of the oocyte. Thus, showing one or more modified proteins might
be critical for oocyte maturation.
In addition to the maturation of oocyte, the development of oocytes has also been
associated with changes in O-GlcNAc levels [11]. A gradual decrease in the O-GlcNAc
levels was observed as during the oocyte progression from the stage I to stage VI along
with a concommitant increase in the activity of O-GlcNAcase. Analysis of the oocyte
proteins of all the stages I-VI has clearly demonstrated the reduction of O-GlcNAc levels
in the high molecular weight proteins (>36 kDa) and herein, this thesis [11]. This reducetion in turn correlates with the metabolic transition of oocyte from glycolytic to gluconeogenic state [33]. In addition, no incorporation of 3H-glucosamine into proteins in the
stage VI suggested very low levels of new O-GlcNAc modification in this stage [96].
Interestingly, a similar phenomenon of change in O-GlcNAc levels was observed during
the transition of cell to malignancy, indicating the fully grown oocyte (stage VI) may
have more characteristics in common with a malignant cell where the regulation of OGlcNAc modification is disrupted [36].
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Chapter 2
Materials and Methods
2.1 Materials:
2.1.1 Reagents:
Reagents used in immunoprecipitation and polyacrylamide gel electrophoresis
were obtained from Biorad (Richmond, CA), Fisher (Atlanta, GA), Pierce (Rockford, IL)
and Sigma (St. Louis, MO). Anti-mouse RL-2 antibody was purchased from affinity Bioreagents (Golden, CO), and CTD110.6 was a generous gift from Dr. Gerald Hart and laboratory at Johns Hopkins University, Baltimore MD. The Immobilized pH Gradient
(IPG) strips and IPG buffer, both in the range of pH 3-10 and pH 6-11 were obtained
from Amershams Biosciences (Piscataway, NJ). Collagenase, Anti-mouse IgM conjugated agarose beads, and streptozotocin were purchased from Sigma (St. Lousie, MO).
Secondary antibodies anti-mouse and anti-rabbit IgG were obtained from Biorad (Hercules, CA). The affinity column material, agarose wheat germ agglutinin beads were
obtained from Vector Laboratories (Burlingame, CA). Nanopure water is used in the
preparation of the buffers. Spectra dialysis tubing of MW 10,000 cut-off and Amicon
centricons of MW 3,000-30,000 cut-off was purchased from Fisher Scientific. The protein standards used were Biorad High range molecular weight and Invitrogen Benchmark prestained protein ladder. All the other reagents used were as per the ACS quality.
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2.1.2 Equipment:
Mini-gel cassette and Genie Electroblotter were obtained from Idea Scientific
(Minneapolis, MN). Conductivity meter and power supply for the electrotransfer were
obtained from Biorad, while UV/ visible spectrophotometer from Pharmacia Biotech.
Amershams EttanTM IPGphorTM Isoelectric focusing system was borrowed from Biochemsitry Department, USF and 6.0 Dexon 3/8 Circle Reserve Cutting surgical needle
along with absorbable suture or non-absorbable suture from Davis and Geck, Inc. (Pearl
River, NY) and Ethicon (Somerville, NJ), were obtained. OptimaTM TL-100 Ultracentrifuge obtained from Beckman Instruments, Inc., (Palo Alto, CA)
2.1.3 Animals:
Female Xenopus laevis frogs were purchased from Nasco (Fort Atkinson, WI) and
maintained at room temperature (20-22 oC) and fed with Frog brittle from Nasco two to
three times a week
2.1.4 Buffers and Solutions:
The oocyte medium called Oocyte Ringers solution 2 (OR-2) (Wallace et al.,
1973) was composed of 82.5 mM NaCl, 2.5 mM KCl, 1.0 mM MgCl2, 5 mM HEPES pH
7.8, 2 mM sodium pyruvate, 10,000 units penicillin, and 10 mg streptomycin. The oocyte
homogenization buffer (Ten β) was comprised of 50 mM Tris–HCl (pH 7.4) containing 5
mM EDTA, the phosphatase inhibitors, 100 mM NaF and 25 mM β-glycerol phosphate;
and in addition, the protease inhibitor 2 mM PMSF, and the O-GlcNAcase inhibitor
5 mM streptozotocin are added before use. Note: The stock solution of 200mM PMSF
was prepared in isopropanol and stored.
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For immunoprecipitation with RL-2 antibody, the immunocomplexed beads were
washed with Wash Buffer 1 containing 150 mM NaCl, 10 mM HEPES pH 7.4, 1% Triton
X-100, 0.1% SDS and Wash Buffer 2 with the same composition as Wash Buffer 1 without salt. For immunoaffinity purification with CTD110.6 antibody required the washing
buffer, radioimmunoprecipitation assay (RIPA) buffer containing TBS (136.9 mM NaCl,
2.7 mM KCl, and 24.8 mMTris-HCl, pH 7.6) along with detergents such as 1%
IGEPAL, 0.5% deoxycholate and 0.1% SDS was used to wash the immunoaffinity
column before elution with 1M GlcNAc in TBS, pH 7.6.
In affinity chromatography, the binding buffer used for equilibrating the agarose
wheat germ agglutinin beads contains 10 mM HEPES, pH 7.8. The used beads were
stored in the storage buffer containing 10 mM HEPES, pH 7.5, 0.15 M NaCl, 20 mM
GlcNAc and 0.08% sodium azide. The proteins of interest were eluted off the column
using a buffer containing 10 mM HEPES, pH 7.8 with 0.3 M NaCl and 0.5 M GlcNAc.
The column can be regenerated with 0.1% acetic acid buffer, pH 3.0 with 1 M NaCl.
In one-dimensional (1D) gel electrophoresis, the samples were diluted with
protein solubilizing mixture (PSM) in the ratio 1:1. PSM is a 50 mM Tris-HCl buffered
solution (pH 7.5) containing 2.5% (w/v) SDS, 25% (v/v) sucrose, 0.25 mg/ml pyronin Y,
25 mM Tris-HCl /2.5 mM EDTA and 1.5% β-mercaptoethanol. The resolving gel required 41.5% stock acrylamide solution (5.6 M acrylamide and 97mM bis-acrylamide),
resolving buffer (2 M Tris pH 8.9), 20% SDS 10% ammonium persulfate and TEMED
(N, N, N’, N’-tetra-methyl-ethylenediamine). For the stacking gel, same materials except
for 4% acrylamide and stacking buffer (0. 5 M Tris pH 6.7) was required. The SDS
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electrophoresis buffer containing 25 mM Tris-base pH 8.3, 195 mM glycine and 0.1%
(w/v) SDS was used to run the SDSPAGE.
In two-dimensional (2D) gel electrophoresis, the samples were solubilized in the
IEF sample buffer containing 7 M urea, 2 M thiourea, 4% (w/v) CHAPS, 60 mM DTT,
0.2% (v/v) IPG buffer (pH 6-11 or pH 3-10), and 0.002%(w/v) bromophenol blue. The
IPG strips were reswelled in rehydration solution containing 8 M urea, 2% (w/v) CHAPS,
0.2% (w/v) DTT, 0.5% (v/v) IPG buffer (pH 6-11 or pH 3-10) and 0.02% bromophenol
blue. The 2nd dimension equilibration buffer contained 2% (w/v) SDS, 50 mM Tris-HCl
pH 8.8, 6 M urea, 30% (v/v) glycerol, 0.002% bromophenol blue and 100 mg of DTT or
250 mg iodoacetamide. The 0.5% agarose sealing solution containing 0.002% bromophenol blue was used to seal the IPG strip on SDS gel. All other solutions and buffers
used were similar to that of 1D-gel electrophoresis.
The molecular weight markers used for molecular weight comparison were used in
either the unstained form or prestained (dye modified) form. The prestaining (modification with dye) of these proteins alters the molecular weight and relative migration (Mr)
through the gel, the relative molecular weights of both forms (normal/prestained) are
presented. The protein standards included carbonic anhydrase (Mr 31 000/ 37 000), ovalbumin (Mr 45 00/50 000), serum albumin (Mr 66 200/ 75 000), phosphorylase b (Mr
97400/ 100 000), β-galactosidase (Mr 116 250/ 150 000) and myosin (Mr 200000/
250000) respectively for unstained or stained.
The gel staining solution, Coomassie blue staining solution contains 80% stock solution and 20% methanol (stock solution contains 1 g of Brilliant blue G250, 11.6 ml of
85% H3PO4 acid and 100 g (NH4)2SO4 diluted to one liter).
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For electroblotting, cold (4oC) transfer buffer containing 50 mM Tris, 192 mM
glycine (pH 8.3) and 20% methanol was used. (Note: The pH of the solution is not measured)
For CTD110.6 immunoblotting, the buffers used were TBS-HT (136.9 mM NaCl, 2.7
mM KCl, and 24.8 mMTris-HCl pH 8.0/ 0.3% Tween-20) and TBSD (136.9 mM NaCl,
2.7 mM KCl, and 24.8 mMTris-HCl pH 8.0/ 0.25% deoxycholate/ 1% Triton X 100/
0.1% SDS). The CTD110.6 antibody, monoclonal mouse IgM was stored at 0.2ug/ul in
TBST (136.9 mM NaCl, 2.7 mM KCl, and 24.8 mMTris-HCl pH 8.0, with 0.05% Tween20)/ 3% BSA in -70 °C freezer until needed. A stock dilution of antibody (1:500) was
prepared in TBST/ 3% BSA/ 0.01% sodium azide stored at 4 °C and used for two weeks
to one month.
The RL-2 immunoblot requires PBST (136.9 M NaCl, 2.7 mM KCl, 5 mM Na2HPO4,
and 2 mM KH2PO4 pH 7.2/ 0.05% Tween-20) and high salt PBST (HSPBST) (479 mM
NaCl, 3 mM KCl, 5 mM Na2HPO4, 2 mM KH2PO4 pH 7.2, 0.05% Tween-20). The RL-2
antibody, monoclonal mouse IgG1 was aliquoted in PBST (136.9 M NaCl, 2.7 mM KCl,
5 mM Na2HPO4, and 2 mM KH2PO4 pH 7.2, with 0.05% Tween-20) and 3% BSA and
stored at -70 °C. A stock antibody dilution of 1: 500 in PBST/ 3% BSA/ 0.01% sodium
azide stored at 4 °C lasts for a month.
The membrane staining solutions are 1% India ink in TBST (0.3% Tween) and 0.2%
Ponceau S stain (stock solution contains 2% Ponceau S in 5% acetic acid) for nitrocellulose, and 0.1% (w/v) Coomassie blue R in 50% methanol and 10% acetic acid is used for
PVDF membranes.
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The gel staining solution, Coomassie blue staining solution contains 80% stock solution and 20% methanol (stock solution contains 1 g of Brilliant blue G250, 11.6 ml of
85% H3PO4 acid and 100 g (NH4)2SO4 diluted to one liter).
2.2 Methods
2.2.1 Oocyte harvesting and isolation:
Mature Xenopus frogs were maintained in the tanks filled with dechlorinated tap
water at room temperature. The animals were fed with Nasco vitamin fortified frog brittle
two or three times per week. To obtain the oocytes, first a healthy frog without surgical
scars or with clearly healed prior incisions was anesthetized by immersing in NaHCO3
buffered solution of MS 222 (500 mg of MS222 and 10 mEq of NaHCO3 in one liter deionized water) in a tank for 10-20 minutes. Later it was placed on its back on a bed of ice,
and the ovarian tissue was surgically removed through incision on the ventral surface.
The muscle incision was sutured with absorbable suture and the skin with non-absorbable
suture. An injection of Xylazine hydrochloride (10 mg/kg) was given intracoelomically.
The animal was transferred to an empty recovery tank and allowed to recover at room
temperature. Once the frog flipped on its stomach, room temperature water was added
until it covered the animal and monitored for 30 minutes. The frog was kept under observation for two–three days, and if apparently normal was transferred back to one of the
common holding tanks until the ovarian sacs were regenerated [19].
The excised ovarian tissue was cut into small sections (~ 1 cm2) and washed with
OR-2 solution to remove all the debris. Then ovarian tissue in fresh OR-2 solution was
incubated in collagenase (1 mg/ml) for approximately 4 hours to free the oocytes from
collagen. Later the turbid supernatant of oocytes freed from ovarian tissue framework
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was carefully decanted without disturbing the sedimented oocytes to remove the unreacted collagenase and fresh OR-2 containing Ca+2 was added. Being smaller in size and
lighter than the other stages, the stage I and II oocytes do not sediment quickly. Therefore, these oocytes in the fresh OR-2 solution can be separated from the rest by a series of
swirling followed by a quick decantation of the supernatant containing mostly stage I and
II oocytes. Oocytes in this supernatant were sorted into stage I and II in a petridish under
a microscope. Typically 1000-1500 stage I oocytes were isolated from a healthy frog.
2.2.2 Homogenization of the oocytes
The sorted oocytes were transferred to a test tube (200 µl) and the liquid carefully
removed with a pipet. Oocytes were then washed twice with two volumes of ice cold Ten
β that was removed by 20 µl pipette, and then followed by the addition of fresh ice cold
Ten β, approximately 1ul per stage I oocyte, and 10 µl per stage VI oocyte was added.
Oocytes were then homogenized on ice in Ten β by rapidly drawing and expelling them
from the 200 µl pipette tip. For stage VI oocytes an equivalent volume (1:1) of ice cold
Freon (1, 1, 2-trichloro-trifluoro-ethane) was added to remove yolk protein and lipid [97],
and the solution mixed thoroughly. The solution is centrifuged at 12,000 x g at 4 °C for
ten minutes to remove the yolk proteins and membrane materials. The aqueous supernatant was carefully collected without disturbing the pellet at the Freon/buffer interface and
stored at -20 °C. Previous work has demonstrated that the Freon does not change the
protein profile in stage VI oocyte [98]. Same procedure was used to homogenize the
stage IV and V oocytes using 5 µl of Ten β per oocyte to lyse the oocytes, and followed
by Freon extraction to remove the yolk. While, the stage II and III were homogenized in
the same manner as the stage I, except the stage III requires 3 µl of Ten β per oocyte.
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2.2.3 Protein Estimation:
The protein concentration of the homogenate was estimated using Bradford micro
protein assay (Biorad). Pure bovine IgG (Biocompare, CA) (stored as 1 mg/ml in H2O at
-20 °C) was used to obtain the standard curve using protein concentrations from 2 ug to
20 ug. First, six dilutions of protein standard were prepared by thorough mixing with 200
ul of reagent and nanopure water. After incubation at room temperature for 5 minutes, the
absorbance was read at 595 nm on a spectrophotometer. In the same way, the sample
solution was prepared in triplicate and absorbances were recorded at 595 nm. The protein
amount in the samples was calculated from the standard curve.
2.2.4 Immunoprecipitation with RL-2 antibody:
The O-GlcNAc modified proteins were immunoprecipitated using mouse
monoclonal RL-2 antibody, monoclonal mouse IgG1 to form an immunocomplex with
the Anti-rabbit IgG preabsorbed Protein A trisacryl beads [99]. All the steps of the procedure were performed at 4°C. Each experiment was performed with three samples. The
immunoprecipitation was carried out using the homogenate of the stage I and a few stage
II (<10%) oocytes, with the final concentration of protein 1-2 µg/ µl using Ten β.
The homogenate was incubated with RL-2 antibody (5 µg for every 1mg of
protein) and protein A trisacryl beads (50 µl) that were preabsorbed by overnight incubation with Rabbit Anti-mouse IgG (50 µg) and left overnight on the rotating mixer. Later
the immunocomplex with the beads was harvested by centrifugation at 10,000 x g for 10
minutes to collect the pellet. This procedure was repeated after each washing step using
Wash Buffer 1 and Wash Buffer 2. Then the pellet was solubilized with PSM as mention29

ed in the above procedure. All the fractions, the supernatant, washes and pellet were
analyzed by silver staining the gel and CTD110.6 antibody immunoblotting.
2.2.5 Immunoaffinity purification using CTD110.6 antibody
This method employed CTD110.6 antibody, mouse monoclonal IgM that specifically binds to the modified proteins to the Anti-mouse IgM conjugated agarose column
[100]. All the steps of the procedure were performed at 4°C. Each experiment was performed with three separate samples. The immunoprecipitation was carried out using the
homogenate of the stage I and a few stage II (<10%) oocytes, with the final concentration
of protein 1-2 µg/µl using Ten β.
First to preclear so as to reduce non-specific binding, the homogenate was incubated with the Anti-mouse IgM conjugated agarose beads for one hour on the rotating
mixer, and centrifuged at 10,000 x g for 10 minutes to collect the supernatant. The precleared homogenate was then incubated with CTD110.6 antibody (5 µg for every 1mg of
protein) and Anti-mouse IgM conjugated Agarose beads (50 µl) for 3 hours on the rotating mixer. Next the slurry was transferred into the column (1.5 cm x 6.5 cm) and the flow
through was collected. The column was then washed twice with five volumes of RIPA
buffer and once with two volumes of TBS. After washing the column, the proteins were
eluted three times, each with two volume of 1 M GlcNAc in TBS after 20 minutes incubation. The eluted fractions were precipitated by overnight incubation with ten volumes
of cold methanol at -20 °C. Samples were centrifuged at 10,000 x g for 15 minutes and
the pellets were solubilized in PSM by vortexing for 1-2 minutes and boiling for two
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minutes. All fractions, the flow through, the washes and the elutions were analyzed by
silver staining and RL-2 immunoblotting.
2.2.6 Affinity chromatography:
The affinity chromatography was based on agarose wheat germ agglutinin column
that specifically binds to all the terminal N-acetyl glucosamine residues on proteins
[101], and thus enriching the sample with proteins of interest. Initially, the affinity purification was performed using binding buffer containing 10 mM HEPES, pH 7.8 and 0.15
mM NaCl (as per the maufacturer’s instructions). Later, the low salt conditions using the
same binding buffer without NaCl were employed for affinity purification of the sample,
in order to enhance binding to the wheat germ agglutinin [102]. Homogenate (typically 1
mg) with a final concentration of approximately 1-2 µg/µl was incubated with 100 µl of
agarose wheat germ agglutinin (WGA) beads for two hours on the rotating mixer. Before
incubation with the protein mixture, the beads were washed with binding buffer to remove salt and N-acetylglucosamine (GlcNAc) present in the storage medium and were
resuspended in the binding buffer. The incubated mixture was poured into a column (1.5
cm x 6.5 cm). Next the affinity column was washed five times with five column volumes
of binding buffer. Elutions were performed with two column volumes of the elution
buffer containing 0.5 M GlcNAc. Then, the eluted beads were regenerated using regeneration buffer at pH 3.0. Once regenerated, the beads were stored in the storage buffer.
The eluted fractions were concentrated and pooled using ultra-centrifugation device
with10,000 MW cut-off. The concentrated samples were solubilized with 2x PSM.
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2.2.7 Differential sedimentation for enrichment of O-GlcNAc modified proteins:
Stage I oocytes were first homogenized in ten β as mentioned in the previous
sections, and centrifuged at 1,000 x g for 10 minutes to remove cell debris and unlysed
cells. The collected supernatant was then centrifuged at 10,000 x g for 10 minutes and the
pellet was stored at -70 oC for further analysis. Later, the supernatant at 10,000 x g was
further centrifuged at 100,000 x g for one hour and the fractions were stored at -70 oC.
All the above fractions were analyzed by 1D/ 2D gel electrophoresis.
2.2.8 One-dimensional gel electrophoresis:
Samples were further separated and analyzed on either 8-10% SDS-polyacrylamide minigel (9.5 cm x 6.5 cm) (SDS-PAGE) that was made following the protocol of
Laemmili [103]. The resolving gel was made from appropriate dilutions of 41.5% stock
acrylamide solution (5.6 M acrylamide and 97mM Bis-acrylamide) with resolving buffer
(2 M Tris pH 8.9), nanopure water, 20% SDS 10% ammonium persulfate and TEMED
(N, N, N’, N’-tetra-methyl-ethylenediamine). The mixture was degassed for a minute
before adding ammonium persulfate and TEMED. The stacking gel was made in a same
manner except the final percent acrylamide was 4%, and stacking buffer (0.5 M Tris pH
6.7) was used instead of resolving buffer. Gels were run at room temperature at 15
mamps for approximately 1-2 hours, usually 40-50 minutes after the dye has completely
left the gel.
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2.2.9 Two-Dimensional Gel Electrophoresis:
For higher resolution, the samples were subjected to two-dimensional (2D) Gel
Electrophoresis. The method has two discrete steps. In the first step (first-dimension), the
proteins were separated based on their isoelectric points using 7cm Immobilized pH gradient (IPG) strips of pH 6-11 or pH 3-10 NL from amershams. The proteins focused at
their characteristic pI on the IPG strip were further analyzed based on their molecular
weight in the second step (second-dimension) using SDS-PAGE.
IEF was performed in four main steps, the sample preparation, the rehydration of
the IPG strips, the sample loading and the isoelectric focusing. First, the sample was prepared by dialyzing against low concentration Tris buffer, pH 7.4 (5 mM Tris, 0.1%
IGEPAL and 1 mM DTT) using dialysis tubing with a 10,000 M.W. cut off to reduce the
concentration of salts including Tris that interferes with IEF. The dialyzed sample was
solubilized with IEF buffer in a ratio of 1:6. The pH range of IEF buffers depends on the
pH range of the used strip. Note: If the samples are too diluted (<3 µg/µl) following dialysis, should be concentrated by ultra filtration or acetone precipitation [104]. The second
step of IEF involved rehydration of IPG strip as per supplier’s instructions. The dry IPG
strip was soaked overnight with the gel-side down in rehydration solution containing the
appropriate IPG buffer with the overlay of DryStrip Cover Fluid. A 7cm IPG strip requires 125 µl of rehydration solution [105].
Sample loading constitutes the third step in isoelectric focusing (IEF). For the
IEF, the IPG strip was first positioned on the Ettan IPGphor Cup Loading Strip Holder as
per the manufacturer’s instructions. The sample was applied to the rehydrated strip by the
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sample cup application method. For a basic IPG strip, the sample was applied at the anodic end and at the center for a whole pH range IPG strip to avoid significant extremes of
pH that can lead to loss of O-GlcNAc modification and/or protein precipitation. The final
step comprises of isoelectric focusing (IEF) of the samples by using Ettan IPGphor Isoelectric Focusing System (Amershams). According to the instructions given in the manual, ‘2D-Gel Electrophoresis using immobilized pH gradients, Principles and Methods’,
the IEF was performed on the rehydrated strip at constant amperage of 50 µA at 20oC,
and ramping the voltage initially in a gradient mode to 500 V for 1 m and 4000 V for 1h
30 m, and later in a step and hold mode to 5000 V for 45 m.
After the IEF, the IPG strip was transferred to 10ml screw capped tube and was
either stored at -70 oC or analyzed by SDSPAGE in the second step. The second dimension consists of a 1 mm thick, 10% laemmili SDSPAGE polymerized in between two
glass plates with one plate protruding out, to position the IPG strip; and 4% stacking gel
with two small wells and a larger well. Prior to positioning the strip on gel, the strip was
incubated in equilibration buffer for first 15 minutes with 100 mg of DTT. This was followed by 15 minutes incubation in equilibration buffer with 250 mg of Iodoacetamide.
Subsequently, the equilibrated strip was briefly immersed in the SDS electrophoresis
buffer to lubricate, and later the plastic ends of the strip were carefully trimmed to adjust
its length according to the size of 2nd dimension. The lubricated strip was then loaded on
to the prestacked second dimension gel with the plastic side against one of the glass
plates and sealed into place using the agarose sealing solution described before. With the
protein standards and sample loaded at left of the gel, the gel electrophoresis was
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performed at amperage of 10 mA for 15 minutes and continued for 40 minutes after the
dye runs off.
2.2.10 Gel Staining methods
The staining was performed usually to obtain overall protein profile of the sample
resolved on SDS PAGE. Generally, the gel was first incubated in the fixing solution to
enhance the staining. The method of staining completely depends on the requirement of
the experiment.
2.2.10.1 Coomassie Blue staining
The gel was fixed in a solution containing 20% methanol, 10% Acetic acid with
constant shaking for a total of 20 minutes changing solutions once after 10 minutes. The
gel was rehydrated by soaking in nanopure water for 15 minutes with constant shaking.
The rehydrated gel was then incubated overnight in the G-250 coomassie blue staining
with 20% methanol with constant shaking. The stained gel was destained for two hours in
deionized water to get rid of the background staining [106].
2.2.10.2 Silver Staining
The proteins separated by SDSPAGE were stained by using Biorad Silver stain kit
(as per the instructions given by the manufacturer) The gel, after electrophoresis was incubated in fixing solution containing 40% methanol and 10% acetic acid for 30 minutes
minimum. The fixed gel was immersed in oxidizing solution (K2Cr207) for five minutes.
The gel was then washed with nanopure water for a maximum of 15 minutes, changing 67 times especially in the first 5 minutes. After washing the excess oxidizer, the gel was
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immediately transferred to the Silver solution containing 8% silver reagent and incubated
for 20 minutes. Next, the gel was quickly rinsed in nanopure water for a maximum of 30
seconds and immediately the developer (6.4 g/200 ml) was added to the gel. The developing solution is changed once brown or smoky precipitate appears. This step was
repeated until a stain of desirable intensity was obtained. Then use 5% acetic acid to stop
the staining for 15 minutes. All steps were performed on a shaker.
2.2.11 Gel Drying
Drying of the gel was done by various methods. In one of the method, the gel was
dried using Idea scientific Gel drying frame. (as per the instructions of manufacturer).
The gel was first incubated in 10% ethanol and 5% glycerol for 30 minutes. The gel was
then sandwiched between the wet gel drying membranes, and left encased in the gel drying plastic frame to dry. In another method, the gel was thoroughly rinsed with nanopure
water and placed on a wet filter paper covered with the wet cellophane paper. The gel
was left in the heated gel dryer (Biorad) for one hour to dry.
2.2.12 Immunoblotting
The analysis of the samples on the SDSPAGE was followed by transfer of the
proteins to nitrocellulose or PVDF membranes. [107] Both the hydrophobic membranes
were first equilibrated in transfer buffer for 15 minutes. The PVDF membrane being
highly hydrophobic was initially wetted by methanol (5 seconds) and followed immersions in nanopure water (5 minutes) with constant shaking. The Genie transfer apparatus
(Idea Scientific) was used to transfer the proteins for 2-3 hours at a constant voltage of 12
volts at 4oC in the cold (4oC) transfer buffer.
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2.2.12.1 CTD110.6 immunoblotting
The blot after the transfer was immediately incubated in the blocking solution,
TBS-HT for 2-3 hours at room temperature with constant shaking. Typically all incubations were carried out in carefully cleaned parafilm boats containing 20-50 ml solution.
Next the blot was transferred to the 1o antibody (CTD110.6 antibody) in TBS-HT at a
dilution of 1:5,000 and incubated overnight at 4 oC with constant shaking. The incubated
blot was then washed 2 x 10 minutes with TBS-D and later 3 x 10 minutes each with
TBS-HT. Next the blot was incubated in the 2o antibody (Goat anti-mouse IgM) at a dilution 1: 15,000 in TBS-HT for 1 hour at room temperature with constant shaking. Followed by the washing step as mentioned above and then the dried blot was treated with the
Super Signal chemiluminescent substrate (Pierce) for 5 minutes again following manufacturer directions. Immediately the blot was dried and transferred to the cassette and
exposed to film for 30 seconds or longer. To demonstrate the specificity of the CTD110.6
antibody, a duplicate blot was produced using the same protocol as above, except the
primary antibody solution contained 15 mM N-Acetylglucosamine as a competing sugar.
2.2.12.2 RL-2 immunoblotting
Nitrocellulose immunoblots using RL-2 antibody were allowed to dry after transfer to improve recovery of antigenic sites. The dried blot was first soaked in the PBS at
70 oC in water bath for one hour with constant shaking. The wet blot was then blocked
using high salt PBST (HSPBST) with 3% BSA at room temperature for two hours with
the constant shaking. Typically all incubations were carried out in carefully cleaned parafilm boats containing 30-50 ml solution. Following blocking the blot was transferred into
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a solution containing the primary antibody, RL-2 in HSPSBT with 3% BSA at a dilution
of 1: 5,000 and incubated with modest shaking for two hours. The incubated blot was
then washed 5 x 10 minutes with HSPBST with 0.01% BSA. The washed blot was transferred to the secondary antibody, goat anti-mouse IgG in PBST with 3% BSA at a dilution of 1: 20,000 at room temperature for one hour. The blot was then washed 8 x 10 minutes with PBST and the dried membrane was treated with Super signal chemiluminescence for 5 minutes. The blot was quickly dried and placed in the cassette and exposed
to the film for half a minute and longer [36].
2.2.13 Wheat germ agglutinin affinity blotting
The proteins resolved by the SDSPAGE were transferred to PVDF (Polyvinyl
difluoride) membrane. The blot was blocked in a TBST (0.05% Tween 20) solution
containing 5% BSA for two hours at room temperature with constant shaking. Once
again, all incubations were carried out in carefully cleaned parafilm boats containing 3050 ml solution. After blocking, the blot was rinsed with TBST, and incubated in HSTBST (1 M NaCl) with the WGA-HRP at 1: 10, 000 dilution [108] for 2 h at room temperature. The blot was then washed 3 x 10 minutes with HS-TBST and then 5 x 10 minutes
TBST. The washed blot was developed at room temperature using freshly prepared 3mM
DAB (diaminobenzidine) and 3% peroxide in 50 mM Tris-HCl (pH 7.6). Typically developing times were from 10 minutes to 20 minutes. The developed membrane was then
washed with PBS and dried.
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2.2.14 Membrane staining methods
Once again, the staining method was used to visualize the overall protein profile
of the sample transferred on to the membrane, and the method of staining was chosen
based on the requirement of experiment.
2.2.14.1 India ink staining:
The nitrocellulose/PVDF membrane was first soaked in PBST with 0.05% tween
20 for 10 minutes. If the membrane is nitrocellulose, it was then treated with 1% KOH
solution for 5 minutes to enhance India ink staining. The blot was incubated in PBS for
30 minutes with one change of solution after 15 minutes. Then the blot was incubated for
one and half an hour at 37 oC and one hour at room temperature with PBST, 0.3% tween
20 with changes of the solution every 30 minutes. On completion of washing, the blot
was incubated overnight in 1% India ink staining solution. The blot that was washed with
PBST twice for a few seconds gives a permanently stained membrane [109]. Note: The
membrane was first stripped with a glycine solution if it had been previously immunoblotted. This staining method is more sensitive than other methods with high level of
detection (100 ng).
2.2.14.2 Ponceau S staining
Ponceau S stain can be used for nitrocellulose membranes with a detection limit
of 1ug protein. First, the membranes were incubated in 2% Ponceau S for 20-30 minutes
until the stained bands appear. Then, the stained membrane was destained in nanopure
water to remove the background. This stain is a reversible.
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2.2.14.3 Coomassie staining
This method is used for staining PVDF membranes with detection limit of 1.5 µg
of protein. The membrane is incubated in 0.1% Coamassie stain for 5-10 minutes. Once
the stained bands appear, it is destained with a 50% methanol/10% acetic acid (v/v)
solution to remove the background.
2.2.15 Membrane stripping methods
The immunoblot was incubated in 200mM glycine, pH 3.0 for 20 minutes at
room temperature with constant shaking. The blot was then washed 3 x 10 minutes with
PBST [110]. For affinity bolt, β-mercaptoethanol method was used. First the membrane
was incubated in the stripping buffer containing 62.5 mM Tris pH 6.8, 2% (w/v) SDS,
and 100 mM β-mercaptoethanol for 30 minutes at 60 oC. Next, the stripped blot was
washed 3 x 10 minutes in TBST
2.2.16 Identification of the protein bands of interest
Once 2D-gels of oocyte (stage I) proteins were sufficiently stained with coomassie so that identification was possible, the protein bands of interest immediately were
excised for protein sequencing. Being sure to wear gloves and taking care not to introduce any contaminants, protein material ( ie. keratin). In order to identify these bands, the
2D-pattern of proteins in coomassie stain was compared to the 2D-pattern of O-GlcNAc
modified proteins in the CTD110.6 immunoblot. The bands that matched the ones in the
immunoblot by the distances traveled in both the dimensions were selected to be sequenced. The selected protein bands were cut as close to the stained portions to get rid of
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extra gel using a razor. Each of these gel pieces containing the protein was then placed
separately into a 1.5 ml eppendroff tube that was previously washed with acetonitrile to
remove dust and keratin, and stored at -20oC.
2.2.17 Mass Spectrometric peptide sequencing and identification of proteins
The protein bands that were identified as O-GlcNAc modified by using the
CTD110.6 immunoblot All the protein bands of interest were excised from the coomassie
stained gel and sent to John Hopkins The peptide sequencing and identification was
performed by the Dr. Stephen A Whelan at John Hopkins University using the MS/MS
peptide sequencing coupled with database search as described in the following three
steps.
1. In gel digest:
The excised protein bands of the G-250 commassie stained 2D-gel were first
chopped into small pieces. Then the gel pieces were destained by washing three times
with 100 mM NH4HCO3 for 10 minutes each and dehydrating with acetonitrile for another 10 minutes. The dehydrated gel pieces were vacuum dried and rehydrated in 20 µl of
10 ng/µl trypsin (Promega, mass spectrometry grade) in 50 mM NH4HCO3 on ice for 45
minutes. Once the gel pieces were hydrated, excess trypsin was removed and gel pieces
covered with 50 mM NH4HCO3, pH 8.0 were left overnight at 37 oC for digestion. Once
digested, the peptides were extracted with 50 µl of 50 mM NH4HCO3 and then, followed
by three washes with 50 µl of 5% formic acid/ 50% acetonitrile solution for 20 minutes
each. The extractions were pooled and vacuum dried. The extracted peptides were suspended in 0.1% Trifluoro acetic acid (TFA) and passed through Vydac C18 silica Micro41

spin columns (The Nest Group Inc.) and eluted with 75% acetonitrile and 0.09% TFA.
The purified peptide mixture was once again vacuum dried.
2. LC-MS/MS Analysis:
The vacuum dried and purified peptides were resuspended in 1% acetic acid and
loaded on a 10 cm x 0.075 mm column packed with 5 µm diameter C18 beads using N2
pressure. The column was then washed with 1% acetic acid and then the peptides were
separated by a 75 minute gradient of increasing methanol at a flow rate of 190 nl/minute
directing effluent into the source (Finnigan LCQ). The LCQ was operated in an automatic
mode collecting a MS scan (2 x 500 ms) of the peptide mixture, followed by two MS/MS
scans (3 x 750 ms) of the two high intensity peptides with a dynamic exclusion set at 2
with a mass gate of 2.0 Da.
3. Mass data analysis:
In order to identify the proteins, the MS/MS data was interpreted using Bioworks
software. The MS/MS spectra of the peptides were searched against several protein database including Xenopus laevis database (downloaded from NCl, National Institutes of
Health at Frederick, MD) using the bioworks software. The MS/MS protein or peptides
spectra were identified based on “Best hits” in the Xenopus laevis database search. The
“Best hits” were those showing high degree of confidence that is the Xcorr > 2.5 and the
dX-corr for the second entry > 0.1 [111]. At the same time, the data was also manually
inspected for accuracy.
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Chapter 3
Results and Discussion
3.1 Confirmation of the presence of high O-GlcNAc modified proteins in the stage I
oocytes compared to the stage VI oocytes per unit mass:
Slawson et. al. [11] have shown the presence of high levels of O-GlcNAc in stage
I oocytes, and a dramatic reduction in the levels during stage progression (I-VI) of oogenesis. As a first step in elucidating the possible role of O-GlcNAc modification in developing oocytes, the initial efforts were focused on isolation and identification of these
modified proteins. Prior to beginning the purification process, a series of experiments
were performed to confirm and reexamine the modified proteins of interest, and to examine the specificity of the proteins to CTD110.6 antibody (Figure 3.1.1 & 3.1.2 respectively). Every experiment was repeated three separate samples to confirm the results.
Several immunostained bands above 30 kDa were reduced in the intensity while progressing from stage I to VI. Figure 3.1.1 shows that the protein bands # 1-14 at
approximately 29, 48, 52, 63, 66, 70, 76, 84, 90, 101, 106, 116, 128, and140 kDa respectively were of initial interest. Competition for antigen binding with 15mM/30mM Nacetylglucosamine for CTD110.6 antibody demonstrated the specificity of all the above
mentioned protein bands. (Figure 3.1.2) For comparison and as a control, the cytosolic
fraction of a glioma cell line (contributed by Aaron Mathews) that is rich in the OGlcNAc modified proteins also clearly demonstrated the specificity, but interestingly
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Figure 3.1.1- CTD110.6 immunoblot of one-dimensional gel separation of proteins
from oocytes at stages I, II, III and VI. Approximately 20 µg of proteins each of
oocytes at stages I, II, III and VI were individually separated on the 8% gel and immunoblotted with CTD110.6 antibody as described in Methods. The figure represents an autoradiogram of the blot showing the pattern of O-GlcNAc modified proteins in oocytes at
different stages and the decreasing trend on O-GlcNAc levels during stage progression of
oogenesis. The arrows on the left-hand side show the protein bands of interest # 1-14 at
approximately 29, 48, 52, 63, 66, 70, 76, 84, 90, 101, 106, 116, 128 and140 kDa
respectively.
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Figure 3.1.2- Competition with 15mM N-Acetylglucosamine to show specificity of OGlcNAc modified to CTD110.6 antibody. Approximately 20 µg each of proteins from
the cytosolic fractions from glioma cell line treated with 8 mM GlcNAc for 3 hours and 9
hours and the oocytes at stage I were individually separated, and immunoblotted with
CTD110.6 antibody in absence and presence of 15mM/ 30mM GlcNAc. The figures
represent the autoradiograms of the blots (a) without GlcNAc, (b) with 15 mM GlcNAc,
and (c) with 30 mM GlcNAc while incubating the membrane with CTD110.6 antibody.
The complete or partial disappearance of the bands in (b) and (c) indicates the specificity
of the O-GlcNAc modified protein bands to CTD110.6 antibody.
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Figure 3.1.3- RL-2 immunoblot of one-dimensional gel electrophoretic separation of
proteins from oocytes at stage I. Approximately 20 µg of protein was separated on the
10% gel and immunoblotted with RL-2 as described in Methods. The figure represents an
autoradiogram of the blot showing a pattern of O-GlcNAc modified proteins in stage I
oocytes similar to that shown by CTD110.6 antibody. The difference is in the intensity of
specific bands especially the bands around 50 kDa. The positions of molecular weight
marker are shown with arrows on left.
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shows quite a different pattern of modified proteins. A similar pattern of oocyte modified
proteins was observed using RL-2, another antibody recognizing with slightly different
affinity but overlapping specificity to CTD110.6 antibody. Since stage I oocytes contained the largest amounts of these proteins per unit mass, these oocytes were used to isolate
the O-GlcNAc modified proteins of interest. A few stage II oocytes (15% by number)
that show a highly similar pattern of the modification were included to increase the amount of starting material so as to improve yields. Even though, the stage I oocytes are relatively abundant in the O-GlcNAc modified proteins, the total amount of these pro-teins in
an oocyte is still small. Therefore, the strategy was to use a minimum number of purification steps to enhance overall recovery of proteins.
First step of the scheme was to examine the two-dimensional (2D) gel electrophoresis ability to directly separate the proteins of interest in quantities sufficient for
sequencing. In addition, the level of detection of coomassie that used to stain the protein
bands to be sequenced is low (1 ug). Depending on the success of this approach, the next
step was to partially purify or enrich using various affinity technologies coupled with 2Dgel electrophoresis. The enrichment techniques attempted were immunoaffinity methods
using the O-GlcNAc specific antibodies such as CTD110.6 and RL-2, affinity chromatography using the lectin, wheat germ agglutinin that specifically binds to the terminal Nacetylglucosamine residues; and differential sedimentation based on association of this
protein with complex high molecular weight aggregates in the cell.
3.2 Two-dimensional gel analysis of the stage I and VI oocytes:
To examine and compare the 2D-pattern of the total proteins in stage I and VI
oocytes, the whole cell homogenates were individually analyzed by 2D-gel electropho47

resis and immunoblotted with CTD110.6 antibody. Both samples were separately resolved by using two IPG strips with different pH ranges while performing IEF. In order to
view all the oocyte modified proteins an IPG strip of full pH range 3-10 (Non-linear) was
used. The non-linear range was initially selected since it gives a better resolution of the
proteins within the range of pH 5-8, the range where generally the majority of cellular
proteins are focused. Surprisingly, the majority of the modified proteins seen on onedimensional SDS PAGE were not present on the final blot. The 2D analysis of stage I at
this pH range 3-10 showed only three faint modified protein bands # 1-3 at approximately
29, 65 and 69 kDa respectively across an approximate pH range 5-8 on probing with
CTD110.6 antibody. (Figure 3.2.1 a) However, the India ink total protein stain of same
blot stripped using the glycine method showed the presence of several other proteins
bands on the membrane. (Figure 3.2.1 b) Similar results were obtained with three separate samples. This suggests that the absence of the other bands of interests might be due
to the unlikely hydrolysis and loss of the modification at the moderately low pH range.
Alternately, and more likely the proteins might have focused off strip due to the steep rise
in the pH near the end of non-linear pH strip, and as we all see later the very basic nature
of the majority of proteins of interest. In addition to above reasons, the proteins get focused slightly at different regions due to the changes in the pH of the IPG buffer used during
the IEF that might also explain the absence of the proteins that focus in pH range 8-10 in
the later 2D-gel electrophoresis [112].
In the same manner, the proteins of stage VI oocytes were analyzed by 2D-gel
electrophoresis and compared to the 2D-patterns of total proteins and O-GlcNAc modified proteins of the stage I oocytes. Similar results were obtained with three separate
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Figure 3.2.1- Two-dimensional gel electrophoresis of oocyte proteins (stage I) using
isoelectric focusing with pH range 3-10 in the horizontal dimension and SDS-PAGE
(10%) in the vertical dimension. Approximately 100 µg of protein from oocytes at stage
I was separated and immunoblotted with CTD110.6 and later the blot was glycine stripped and stained with India ink as described in Methods. Figures (a) Autoradiogram showing three faint bands at 29, 65 and 69 kDa respectively, and (b) India ink stain showing
the overall 2D-pattern of the proteins of oocyte stage I. On the left hand side of the gel,
20 ug of the stage I was separated on one-dimension acts as reference.
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Figure 3.2.2- Two dimensional gel electrophoresis of oocyte proteins (stage VI) by
isoelectric focusing with pH range 3-10 in the horizontal dimension and SDS-PAGE
(10%) in the vertical dimension. Approximately 100 µg of protein from oocytes at stage
VI was separated and immunoblotted with CTD110.6 and later the blot was glycine
stripped and stained with India ink as described in Methods. Figures (a) Autoradiogram
showing four bands # 1-4 at approx. 32, 35, 45 and 66 kDa respectively, and (b) India ink
stain showing the overall 2D-pattern of the proteins of oocyte stage VI. On the left hand
side of the gel, 20 ug of the stage VI was separated on one-dimension acts as reference.
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samples. Once again, the CTD110.6 immunoblot of stage VI oocyte proteins on the 2Dgel with pH range of 3-10 showed four small bands at approximately 32, 35, 45 and 66
kDa across an approximate pH range 5-8. (Figure 3.2.2 a) While the India ink stain of the
stripped membrane gave the overall 2D-picture of the stage VI oocyte proteins. (Figure
3.2.2 b) In comparison to 2D-pattern of stage I oocyte proteins, the 2D-pattern of stage
VI was once again quite different as clearly shown in India ink stain (Fig 3.2.2 b). Particularly, the protein bands of stage I oocytes that are focused at the extreme right of the
membrane (around pH 10) were completely absent in stage VI oocytes. Careful
examination of the India ink stains of the glycine stripped blots of stage I and stage VI
oocytes have showed a large fraction of the stage I oocyte proteins, unlike that of stage
VI were focused mainly at cathodic end of the IPG strip indicating that majority of stage I
oocyte proteins are basic in nature.
Assuming that most of the O-GlcNAc modified proteins of interest in stage I were
basic in nature and thus, suggesting that the proteins were focused off the IPG strip, the
more basic range of pH 6-11 was selected for IEF. The stage I analyzed within this pH
range showed the majority of the modified proteins resolved into 12 discrete protein
bands within the pH range of 8-10. (Figure 3.2.3 a) These protein bands were numbered
as 1-2, 3a, 3b, 7, 8a, 8b, 8c, 9a, 9b, and 10 as indicated in figure were approximately at
28, 35, 37, 49, 55, 58, 62, 67, 91 and 98 kDa respectively. Among these bands, the bands
# 1-3 are clustered together (as seen in Figure 3.2.3 b) originated from the big band # 1 at
29 kDa in 1D-gel, and the bands # 4-10 corresponds to bands # 2-6 and 9-11 respectively in the 1D-gel. However, the high molecular weight bands (> 100 kDa) do not appear due to proteolytic degradation or precipitation of these proteins during IEF. This is
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Figure 3.2.3- Two-dimensional gel electrophoresis of oocyte proteins (stage I) by
isoelectric focusing with pH range 6-11 in the horizontal dimension and SDS-PAGE
(10%) in the vertical dimension. Approximately 100 µg of protein from oocytes at
stage I was separated and immunoblotted with CTD110.6 and later the blot was glycine
stripped and stained with India ink as described in Methods. Figures (a) Autoradiogram
showed the modified proteins mainly focused at approx. pH 8-10, and 12 distinct bands #
1-2, 3a, 3b, 7, 8a, 8b, 8c, 9a, 9b and 10 were identified at 28, 35, 37, 49, 55, 58, 62, 67,
91 and 98 kDa respectively, and (b) India ink stain showing the overall 2D-pattern of the
proteins from stage I oocyte. On the left-hand side of gel, 20 µg of protein of stage I was
separated on one-dimension acts as reference.
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Figure 3.2.4- Two-dimensional gel electrophoresis of oocyte proteins (stage VI) by
isoelectric focusing with pH range 6-11 in the horizontal dimension and SDS-PAGE
(10%) in the vertical dimension. Approximately 100 µg of protein from oocytes at
stage VI was separated on 10% two-dimensional gel and analyzed by CTD110.6
immunoblotting and later the blot was glycine stripped and stained with India ink as
described in Methods. Figures (a) Autoradiogram showed the modified proteins mainly
focused at approx. pH 7-10, and showing band # 1, 2, 3a. 3b. 4a-c, 5, and 6 at around 22,
25, 26, 43, 49, 63 and 65 kDa respectively with pI 7.8, 8.8, 8.2, 8.4, 7.1, 7.9, 8.5, 9.1, 6.9
and 10 resp.; and (b) India ink stain showing the overall 2D-pattern of the proteins of
oocyte stage I. On the left-hand side of the gel 20 µg of protein of stage VI was separated
on one-dimension acts as reference.
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the limitation of the 2D-technique that was used. The India ink stain of the stage I have
shown that most of the basic proteins were O-GlcNAc modified proteins. (Figure 3.2.3 b)
Thus, the results of the 2D separation with pH range 6-11 substantiated the earlier findings, and indicated the majority of the oocyte proteins from a stage I oocyte were basic in
nature, like most of the ribosomal proteins [113].
While the stage VI oocyte proteins in pH range 6-11 were resolved into a very
different pattern to that of stage I. In stage VI, the majority of proteins focused within pH
range of 7-10, with bands that were numbered as 1, 2, 3a, 3b, 4a-c, 5, 6 and 7 at approximately 22, 25, 26, 43, 49 63 and 65 kDa respectively with approximate pI 7.8, 8.8, 8.2,
8.4, 7.1, 7.9, 8.5, 9.1, 6.9 and 10 respectively. (Figure 3.2.4 a) Once again, the India ink
stain of the stage VI oocytes have showed quite a different 2D-patterns of whole oocyte
proteins from that of the stage I oocytes. (Figure 3.2.4 b) In addition to the differences in
isoelectric points (pIs) of the proteins, there were fewer O-GlcNAc modified proteins of
stage VI oocytes were apparent.
3.3 Immunoprecipitation with RL-2 antibody
Since, the proteins separated from the whole homogenate were not enough and
sufficient to see by the coomassie staining, we felt the need to enrich the samples with OGlcNAc modified proteins. Initially, the enrichment of O-GlcNAc modified proteins was
attempted by the immunoprecipitation with O-GlcNAc specific antibodies such as RL-2
antibody. The immunoprecipitations with RL-2 antibody was successful in enriching at
least some of O-GlcNAc modified proteins of interest as shown by results in the
CTD110.6 immunoblot (Figures 3.3.1 a). Approximately 20 µg of protein from oocytes at
stage I in lane 1, one tenth of the total immunoprecipitate in lane 2, and approximately 20
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µg of supernatant in lane 3 (this amount was estimated taking into account the dilution
and the concentration of original sample) were separated on 8% SDS PAGE and immunoblotted with CTD110.6 antibody. The second lane containing immunoprecipitate
showed a few of the protein bands of interest namely those at 37, 54 and 62 kDa. The
high intensity bands at 50 and 75 kDa in the same lane were of denatured antibodies. The
RL-2 immunoprecipitation performed without the sample (the negative control) clearly
showed the presence of these bands (Figure 3.3.1 c). Thus, the presence of foreign proteins such as heavy chains of the denatured antibodies, which get resolved at nearly the
same regions as proteins of interest in one-dimensional gel electrophoresis interfered with
the detection of the O-GlcNAc modified proteins.
In addition, huge difference in the band intensities of immunoprecipitate and
supernatant lanes in the silver stain clearly indicated large portions of O-GlcNAc modified proteins remained in the supernatant. (Figure 3.3.1 b) The huge protein band at
around 60 kDa in supernatant of the silver stain (shown by an arrow in Figure 3.3.1.b)
appeared to be ‘Protein A’ conjugated to trisacryl beads used in RL-2 immunoprecipition.
This band appears as a large non-illuminated area in the same region of supernatant lane
on immunoblotting with CTD110.6 antibody (Figure 3.3.1.a). Since all the protein bands
of interest in that region were completely concealed by this large Protein A band, it becomes difficult to estimate the O-GlcNAc modified proteins remaining in supernatant. In
order to reduce the contamination with the Protein A, immunopurification by column
method was attempted. But also gave poor results (Data not shown). Increasing the RL-2
concentrations in immunoprecipitation also did not significantly improve the yields, but
increased the level of interference with immunoblot detection. (Data not shown) Thus,
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Figure 3.3.1- One-dimensional gel electrophoresis of the RL-2 immunoprecipitate of
stage I oocytes. Approximately 20 µg of protein from oocytes at stage I in lane 1, one
tenth of the total immunoprecipitate in lane 2, and approximately 20 µg of supernatant in
lane 3 (this amount is estimated taking into account the dilution and the concentration of
original sample) were separated on 8% SDS PAGE and immunoblotted with CTD110.6
antibody and stained with silver as described in Methods.(a) Autoradiogram of
CTD110.6 immunoblot and (b) silver stain showing few protein bands of interest approximately at 37, 59 and 62 kDa in the RL-2 immunocomplex; and (c) Autoradiogram of
CTD110.6 immunoblot with RL-2 immunocomplex and RL-2 immunocomplex without
oocyte proteins (representing a negative control) were loaded in lane 1 and 2 respectively,
showing the bands at 50, 75 and 100 kDa might be the bands of antibody.
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another approach was investigated.
3.4 Immunoaffinity purification using CTD110.6 antibody
To reduce the contamination of the samples with the foreign proteins (antibodies),
the separation was performed using an anti-mouse IgM-agarose immunoaffinity column,
where the antibody is covalently linked to the agarose bead while retaining its ability to
specifically bind to CTD110.6 antibody (IgM sub-type). The proteins were eluted with a
solution of TBS buffer containing 1 M N-acetylglucosamine and concentrated by methanol precipitation that also removes the majority of N-acetylglucosamine. All the collected column fractions and the precipitated elutions were analyzed by RL-2 immunoblotting
and silver staining (Figure 3.2.2 a and b). Approximately 20 ug of stage I oocyte proteins
(original sample) in lane 1, one half of the eluted proteins in lanes 2, 3 and 4, and approximately 20 ug of flow through (this amount was estimated taking into account the dilution and the concentration of original sample) in lane 5, one tenth of RIPA washes in lane
6 and 7, were separated on 8% SDS PAGE and analyzed by RL-2 immunoblotting. The
analysis showed most of the O-GlcNAc modified proteins were in the flow through and
washes (Figure 3.4.1.a). Thus, indicating poor binding of O-GlcNAc modified proteins to
the column. Once again, the band at 60 kDa in both the flow through and washes that
concealed the protein bands of interest. While some of this appears to be due to leaching
of antibody from the column, it also represents the presence of BSA. BSA used as
stabilizer in the stock solution of the CTD110.6 antibody used in the immunoprecipitation. Since so much of the proteins of interest were found in the flow through, this material was incubated with a new set of beads to see if the yield could be improved. On the
analyzing the collected fractions, once again the elutions of the immunoaffinity puri57

Figure 3.4.1- One-dimensional gel electrophoresis of the CTD110.6 immunoaffinity purified proteins of stage I oocytes. Approximately 20 ug of stage I oocyte
proteins (original sample) in lane 1, one half of the eluted proteins in lanes 2, 3 and 4,
and approximately 20 ug of flow through (this amount was estimated taking into
account the dilution and the concentration of original sample) in lane 5, one tenth of
RIPA washes in lane 6 and 7, were separated on 8% SDS PAGE and analyzed by RL2 immunoblotting and silver stained as described in Methods. (a) Autoradiogram of
RL-2 immunoblot (8% gel) showing few protein bands approximately between 50-60
kDa in the immunopurified sample and most of the modified proteins in the flow
through and washes; (b) silver stain of 10% SDS Gel showing the presence of majority of proteins in the flow through. (c) Autoradiogram of RL-2 immunoblot (8% gel)
whose lanes representing fractions of repeated immunoprecipitation of flow through.
The faint bands around 50-60 kDa indicated no improvement in the yield using
immunoaffinity purification of the flow through.
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fication showed very weak bands at 50 kDa, and with majority of the proteins again in
the flow through and washes. (Figure 3.4.1 c) The results was also confirmed with silver
staining that demonstrated very low protein content in the elutions compared to the flow
through. (Figure 3.4.1 b)
In an attempt to improve the yield, the batch-wise incubation method was adopted
as a way of exposing more of the column material to the proteins for longer periods of
time. Most of the protein bands of interest were detected on analyzing CTD110.6 immunoaffinity eluants following the same procedure of RL-2 immunoblotting. Again some of
the bands were concealed by the heavy chains of antibodies at 60 and 100 kDa. These
bands are confirmed as bands of the antibodies because similar bands at region of same
molecular weight appeared when the anti-mouse IgM-agarose beads were resolved by
SDS PAGE, and immunoblotted with RL-2 antibody (Figure 3.4.2 a). In addition, the
presence of considerable amounts of O-GlcNAc modified proteins in the flow through
indicated that significant amounts of proteins were still not being captured with this techique (Figure 3.4.2 a). Further purification of the immunopurified material by 2D-gel electrophoresis showed that the O-GlcNAc modified proteins were not in most cases sufficiently separated from contaminating immunoglobulin and BSA, which was clearly
visible in the RL-2 immunoblot as shown in the Figure 3.4.2 b. Three protein bands on
the extreme right of the membrane which are indicated by the arrows in the Figure 3.4.2 b
appeared to be well separated in the immunoblot. However, the India ink stain of this blot
after glycine stripping showed a huge smear in that region indicating the presence of
additional protein and would thus, confound sequencing of the O-GlcNAc modified
proteins (Data not shown). These streaking and smear that were also observed in the
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Figure 3.4.2- One-dimensional and two-dimensional gel electrophoresis of CTD110.6
immunoprecipitate (Batch-wise incubation method) of stage I oocytes.
Approximately 20 µg of protein from oocytes at stage I, a quarter of the total immunoprecipitate collected, and a volume of supernatant representing 20 µg compared to Homogenate (stage I) were loaded in the first three lanes of 10%1D-Gel; and nearly half of the
immunocomplex was separated on 10% 2D-gel along with 20 ug of proteins of oocytes at
stage I on left hand side of the gel as a reference and immunoblotted with RL-2 antibody
as described in Methods. Autoradiograms of (a) 1D-gel showing most of the protein
bands of interest in immunocomplex along with the bands of foreign proteins, and (b)
2D-gel showing vertical and horizontal streaking of the foreign proteins that overlaps the
protein bands of interest pointed out using arrows.
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immunoblot might be due the presence of the agarose beads conjugated anti-mouse IgM
in the immunoprecipitate. Even though, kits are available to remove some of the contaminating proteins, typically not all immunoglobulin and albumin were removed. Therefore,
it was decided not to pursue the method, because of already low yields and potential loss
of sample in additional steps.
3.5 Affinity chromatography
To overcome the problems of low yields and contamination with the foreign
proteins mainly antibody, lectin affinity chromatography using agarose wheat germ
agglutinin was used in an attempt to enrich the samples with O-GlcNAc modified
proteins. This procedure has been used with some success in non-Xenopus somatic cell
systems [114]. To first assess the potential effectiveness of this tool for our Xenopus
system, oocytes stage I and stage VI were analyzed by the wheat germ agglutinin (WGA)
affinity blotting. WGA binds to all glycoproteins with terminal N-Acetylglucosamine
residues and thus, can bind to both O-GlcNAc modified proteins and glycoproteins with
terminal GlcNAc on N-linked oligosaccharide chains. As expected the pattern of modified proteins from the affinity blot was similar but not identical to that observed in the
immunoblots with CTD110.6 and RL-2 antibodies (Figure 3.1.1 and 3.1.3). For instance,
the bands at 50 and 97 kDa of stage VI oocytes shown by arrows in Figure 3.5.1 appeared
in the affinity blot, but did not show up in the previous shown immunoblots. While
appearance was at a similar molecular weight on 1D-analysis, the proteins seen at 50 and
97 kDA in stage VI are likely not the same as those in stage I samples. This is likely due
to the affinity of WGA for all the carbohydrate containing proteins, with terminal Nacetylglucosamine residues on some N-linked carbohydrate containing proteins.
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Figure 3.5.1- WGA Affinity blot of the oocytes at stages I and VI. Approximately 20
µg of proteins from oocytes at stage I and stage VI were separated on the 10% SDS gel
and probed with WGA-HRP. The blot showed all the bands that appeared on the
immunoblots with CTD110.6 and RL-2 in comparatively lower intensities due to the low
sensitivity of colorimetric detection. The bands of stage VI shown by arrows are absent in
the CTD110.6 immunoblot of the same system.
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Moreover, only the most prominent bands were visible on the affinity blot due to lower
sensitivity of the colorimetric detection method suggested for use by manufacturer.
Attempts to use the chemiluminescent detection resulted in very high backgrounds that
could not be sufficiently reduced with the standard blocking agents such as BSA, tween
20. (data not shown) Note non fat dry milk a popular blocking agent cannot be used with
CTD110.6 and RL-2 antibodies, since one or more carbohydrates in the solution reduces
the antibody signal and gives high background.
Once the affinity of WGA for the proteins of interest was verified, the affinity
purification was initially performed at approximately 0.15 M NaCl as per the manufacturer’s instructions, and later the concentration of salt was reduced to less than 0.1 M
NaCl as suggested by a published study [102], in order to maintain the weak intermolecular interactions in protein complexes and improve yields. The results of both the
experiments as shown in Figure 3.5.2 a & b demonstrated that low salt conditions improved yields of affinity purification. In both experiments, the proteins bound to the
column were eluted using the binding buffer containing 0.15 M NaCl and 0.5 M GlcNAc.
The collected fractions were pooled, desalted and concentrated by ultra-filtration using
centricon-10 in order to proceed to 2D-gel electrophoresis, the next purification step.
Once again, all the collected fractions were analyzed by CTD110.6 immunoblotting are
shown in Figures 3.5.2 a and b represents the affinity purification at low salt (> 0.1 M
NaCl) and high salt (0.15 M NaCl) conditions respectively. The second lane in the Figure
3.5.2 a shows the sample from the pooled elution contained all of the target bands,
whereas the second lane in the figure 3.5.2 b did not show the bands at 54, 57 and 82
kDa. Thus, indicating that low salt binding conditions maximized both the yield and
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Figure 3.5.2- One-dimensional gel electrophoresis of affinity purified proteins from
oocytes at stage I. Approximately 20 µg of proteins from oocytes at stage I, a quarter of
the pooled elution of the affinity purified proteins at two different conditions, 0.1 M NaCl
and 0.15 M NaCl, estimated volume containing 20 µg calculated using the concentration
of the homogenate (stage I) were separated in the first three lanes of the 10% gel and
immunoblotted with CTD110.6 antibody as described in Methods. Autoradiograms of the
affinity purification (a) at low salt conditions (< 0.1 M) showing almost all the protein
bands of interest in elutions and (b) high salt conditions (0.15M) salt showing bands at
35, 59, 69 and 97 kDa only.
(a) Affinity purification
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number of O-GlcNAc modified proteins. Therefore, the enrichment was qualitatively
successful in concentrating all the modified proteins of interest. However, the yield was
only 20% apparently due to the loss of proteins by aggregation and precipitation during
the concentration process. Hence, in order to acquire sufficient amounts of protein for sequencing, with this technique we would need to start with a larger amount of the oocyte
material which unfortunately is a limiting factor in our process of purification.
3.6 Differential Sedimentation
To overcome the problem of low initial proteins available from stage I oocytes, an
another method was sought that minimized sample loss while still achieving enrichment
of O-GlcNAc modified proteins. To this end, it was noted that the proteins of interest
tended to precipitate in stored homogenates suggesting that the proteins tend to form high
molecular weight complexes. Based on this hypothesis, the enrichment of the O-GlcNAc
modified proteins was attempted by simple differential sedimentation. First, centrifugation of the lysed oocytes at 1,000 x g for 10 minutes was performed in order to sediment
any unlysed cells and large cell debris. The supernatant-1 (that is collected after 1,000 x
g) was then centrifuged at 10,000 x g for another 10 minutes, to further fractionate the
homogenate (stage I oocyte) into supernatant-10 and pellet-10. The supernatant-10 was
fractionated again by ultra-centrifugation at 100,000 x g for one hour into supernatant100 and pellet-100. All the fractions were resolved on 10% SDS PAGE and analyzed by
CTD110.6 immunoblotting (Figure 3.5.1 a). Later, this blot was stripped with glycine
solution, and stained with India ink (Figure 3.5.1 b). All the lanes contained approximately 20 µg of oocyte proteins. The O-GlcNAc protein pattern in the supernatant-1 and
supernatant-10 was similar to the earlier patterns of stage I. But the pellet-10 in the lane 2
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Figure 3.6.1- One-dimensional gel electrophoresis of proteins from oocytes at stage I
fractionated by Differential Sedimentation. The homogenate of the stage I oocytes
(after 1,000 x g) was fractionated by the centrifugation at 10,000 x g and 100,000 x g,
and 20ug each of the collected supernatants and pellets were separated on 10% ID-Gel
electrophoresis and analyzed by CTD110.6 immunoblotting and later glycine stripped
CTD110.6 blot was stained by India ink as described in Methods. (a) Autoradiogram
showing few O-GlcNAc modified proteins in the pellet at 10,000 x g and the distribution
of protein bands of interest in both the supernatant and the pellet collected at 100,000 x g
where majority of O-GlcNAc modified proteins were found in pellet; (b) India ink stain
of the glycine of the blot showing the concentration of the proteins bands of interest in
the pellet at 100,000 x g.
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of India ink stain (Figure 3.5.1 b) showed the presence of large amounts of unmodified
proteins indicating the centrifugation at 10,000 x g concentrated the proteins of interest in
the supernatant-10. Thus, the centriguation of lysed oocytes at 10,000 x g can be performed to remove the unlysed oocytes and debris without significant loss of desired
proteins. In contrast, the ultra-centrifugation of supernatant-10 at 100,000 x g for 1 hour
had sedimented the majority of modified proteins as shown in the Figure 3.6.1 a. Interestingly, the India ink stain (Figure 3.6.1 b) revealed the fact that the majority of the
oocyte’s unmodified proteins remained in the supernatant-100. Therefore, this method
not only enriched the target proteins, but also minimized the loss of these proteins.
The enriched samples analyzed by 2D-Gel Electrophoresis across the pH range 611, as expected showed the same 2D- pattern of the modified proteins as that of whole
homogenate of stage I oocytes (Figures 3.6.2 a and 3.2.3 a). In addition, the majority of
the proteins were basic in nature and were better resolved on the IPG strip, pH 6-11 as
shown in Figure 3.6.2 a. Once again, the modified proteins were mainly focused in the
pH range 8-10. Interestingly, these protein bands appeared at slightly lower molecular
weight than that of the whole homogenate. The high electrophoretic mobility of the proteins might be due to the presence of few non-modified proteins in the sample. The
estimated molecular weights of these protein bands # 1-7, 8a, 8b, 9a, 9b, 10, 11a and 11b
in Figure 3.6.1a were 21, 23, 36, 46, 47, 53, 52, 54, 83, 87 and 108 respectively. In
addition, the intensity of protein bands of the pellet-100 (figure 3.6.2 a) is higher than that
of the homogenate (Figure 3.2.3) showing successful enrichment of O-GlcNAc modified
proteins. Competition experiments with 15 mM GlcNAc demonstrated specificity through the reduction in the intensity of all the bands as seen in Figure 3.6.2 b, especially in
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Figure 3.6.2- Two-dimensional gel electrophoresis of pellet at 100,000 x g from stage
I oocytes by isoelectric focusing with pH 6-11 in the horizontal dimension and SDSPAGE (10%) in the vertical dimension. Approximately 100 µg of protein from oocytes
at stage I was separated and analyzed by CTD110.6 immunoblotting without and with 15
mM GlcNAc as described in Methods. (a) Autoradiogram of immunoblotting in the
absence of GlcNAc showed the modified proteins mainly focused at approx. pH 8-10,
and 10 distinct bands # 1-4, 5a, 5b, 6, 7, 8a, 8b, 9a, 9b,10, 11a and 11b were identified at
21, 23, 36, 46, 47, 53, 52, 54, 83, 87 and 108 kDa respectively. On the left-hand side of
gel, 20 µg of protein of stage I was separated on one-dimension acts as reference. (b)
Autoradiogram of immunoblotting in the presence of 15mM GlcNAc showed the
modified proteins mainly focused at approx. pH 8-10, showing all bands nearly reduced
in the intensity.
(a) Without GlcNAc
kDa
11a

116.25
97.4
9a

66.2
8a

11b

10
9b

8b 7

6
4

5a
3

45

5b

2
1

Homogenate
6
Stage I
oocytes

11

(b) With 15mM GlcNAc
kDa
116.25
97.4
66.2
45

Homogenate
Stage I 6
oocytes

11

68

Figure 3.6.3- Two-dimensional gel electrophoresis of pellet at 100,000 x g from stage
I oocytes by isoelectric focusing with pH 3-10(NL) in the horizontal dimension and
SDS-PAGE (10%) in the vertical dimension. Approximately 100 µg of protein from
oocytes at stage I was separated and analyzed by CTD110.6 immunoblotting as described
in Methods. (a) Autoradiogram of immunoblot showed all the bands focused at the
extreme right due to the non-linearity of the IPG strip. On the left-hand side of gel, 20 µg
of protein of stage I was separated on one-dimension acts as reference.
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the case of bands # 5a, 5b, 11a, 11b and 4.
In addition, the 2D-Gel Electrophoresis using a full range IPG strip, pH 3-10
(non-linear) again showed the majority of the proteins bands of interest focused across
the pH range 8-10 substantiating that most of the modified proteins are basic in nature.
(Figure 3.6.3) However, the protein bands of interest are not well separated due to the
sharp rise in the pH of the non-linear IPG strip (with an extended region across pH 5-8).
Since the extended region on the IPG strip was pH 5-8, some of the neutral and weakly
acidic proteins did separate (Highlighted by an arrow in the Figure 3.6.3). Especially the
band 3a at pH 6-7 spotted in 2D-gel analysis of the homogenate (stage I) showed up once
again in this 2D-gel (as shown with an arrow in Figure 3.2.3 a).
3.7 Identification and selection of the modified protein bands for sequencing
Once the scheme of purification was finalized as shown in the flow diagram,
Figure 3.7.1, the proteins were isolated by differential sedimentation coupled with 2Dgel electrophoresis and coomassie stained for peptide sequencing by mass spectrometry.
The 2D-separated proteins from stage I oocytes that are sufficiently stained with Coomassie nearly showed all the fifteen protein bands of interest. (Figure 3.7.2) Since the stained protein pattern was very much similar to the 2D-patterns observed earlier, the protein
bands of interest could be easily identified by superimposing the CTD110.6 immunoblot
of the stage I oocyte and by their positions on the gel. The identified protein bands shown
in the Figure 3.7.2 by using arrows were carefully excised wearing gloves to avoid contamination.
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Figure 3.7.1- Scheme for isolation and identification of the O-GlcNAc modified
proteins
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Figure 3.7.2- Two-dimensional gel electrophoresis of pellet at 100,000 x g from stage
I oocytes by isoelectric focusing with pH 6-11 in the horizontal dimension and SDSPAGE (10%) in the vertical dimension. Approximately 100 µg of protein from oocytes
at stage I was separated on 10% two-dimensional gel, and stained by coomassie as described in Methods. The stain showed all the fifteen distinct bands # 1-4, 5a, 5b, 6, 7, 8a,
8b, 9a, 9b,10, 11a and 11b were identified at 21, 23, 36, 46, 47, 53, 52, 54, 83, 87 and
108 kDa respectively, mainly focused at approx. pH 8-10. On the left-hand side of gel, 20
µg of proteins of stage I was separated on one-dimension acts as reference.
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3.8 Mass Spectroscopy and database search
Gel containing proteins were treated with trypsin and extracted as described in the methods. The in-gel digested peptides of four protein bands were analyzed by LC-MS/MS
and the MS/MS was interpreted using Bioworks software. All the MS/MS spectra identifying proteins or peptides reported in the appendix C were “best hits” or “best matches”
in a Xenopus database search with an Xcorr > 2.5. The spectral data were also manually
inspected for accuracy. First, the mass fingerprint of trypsin digested peptides was obtained, and then 5 to16 peptides that are easily ionizable were fragmented further. The
fragmentation of peptides resulted in two types of peptide fragment ions, the N-terminal
and the C-terminal ions. These fragment ions were labeled based on the type of bond
cleavage as a, b and c for C-terminal ions and x, y and z for N-terminal ions as shown in
the Figure 3.8.1. These peptide fragment ions were fed into the mass spectroscopy
instrument to obtain a CID (Collision induced dissociation) spectrum of each peptide.
The spectrum of each peptide revealed the peaks of all the fragments, from a molecular
ion to a final product ion formed during fragmentation. Moreover, this dissociation into
the peptide fragment ions helps to differentiate the isomers of amino acids or amino acids
with nearly the same molecular masses, for example isoleucine from leucine and
glutamine from lysine respectively.
In order to identify a protein, we need both the mass fingerprint of the protein (by
MS scan) and the spectra of few peptide spectra for a given protein (by MS/MS scan).
Figures 3.8.2 & 3.8.2, and Tables 3.8.1 & Table 3.8.2 provides an example of mass data
analysis of one of the protein identified as Vg1 RNA binding protein variant A
(Vg1RBP). The spectral data for rest of the identified proteins are given in Appendix C.
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Figure 3.8.1- General fragmentation pattern of peptide and sequence nomenclature
for mass ladder

Figure 3.8.2- MS/MS spectrum of a protein band # 9a identified as Vg1 RNA
binding protein variant A. CID spectrum/ product ion spectrum of a peptide
ITGHFYASQLAQR of the Vg1 RBP showing the peaks of all the peptide fragment ion
in the order of their molecular masses.
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Table 3.8.1- Mass data of a peptide of Vg1 RBP variant A. Table lists out the masses
of all the peptide fragment ions of the peptide ITGHFYASQLAQR

AA
I
T
G
H
F
Y
A
S
Q
L
A
Q
R

M+nH
115.10
216.15
273.17
410.23
557.30
720.36
791.40
878.43
1006.49
1119.57
1190.61
1318.67
1474.77

A
86.10
187.14
244.17
381.23
528.29
691.36
762.39
849.43
977.48
1090.57
1161.61
1289.66
1445.77

A*
69.07
170.12
227.14
364.20
511.27
674.33
745.37
832.40
960.46
1073.54
1144.58
1272.64
1428.74

Ao
68.09
169.13
226.16
363.21
510.28
673.35
744.38
831.42
959.47
1072.56
1143.60
1271.65
1427.75

B
114.09
215.14
272.16
409.22
556.29
719.35
790.39
877.42
1005.48
1118.56
1189.60
1317.66
1473.76

B*
97.07
198.11
255.13
392.19
539.26
702.33
773.36
860.39
988.45
1101.54
1172.57
1300.63
1456.73

Bo
96.08
197.13
254.15
391.21
538.28
701.34
772.38
859.41
987.47
1100.55
1171.59
1299.65
1455.75

C
131.12
232.17
289.19
426.25
573.31
736.38
807.42
894.45
1022.51
1135.59
1206.63
1334.69

X
1404.67
1303.62
1246.60
1109.54
962.47
799.41
728.37
641.34
513.28
400.19
329.16
201.10

Y
1491.77
1378.69
1277.64
1220.62
1083.56
936.49
773.43
702.39
615.36
487.30
374.22
303.18
175.12

Y*
1474.74
1361.66
1260.61
1203.59
1066.53
919.46
756.40
685.36
598.33
470.27
357.19
286.15
158.09

Yo
1473.76
1360.68
1259.63
1202.61
1065.55
918.48
755.42
684.38
597.35
469.29
356.20
285.17
157.11

Table 3.8.2- Peptide sequences of Vg1 RBP. Sequences of sixteen peptides of Vg1 RBP
along with their ionic masses, positions, mass percentages and amino acids percentages
were given. The total protein coverage of 20.62% by mass is a decent % to obtained the
sequence of the protein.

Sequence

MH+

ESKIPFTGQFLVK 1493.84
IPFTGQFLVK
1149.67
AIDTLSGK
804.45
VIEVEHSVPK
1136.63
PQSEVPLR
925.51
FTEEIPLK
976.54
ILAHNNFVGR
1140.63
FAGASIK
693.39
IAPAEGPDAK
968.51
MVIITGPPEAQFK 1430.77
LKEENFFGPK
1208.63
EENFFGPK
967.45
VPSYAAGR
820.43
DQTPDENDQVVVK1486.70
ITGHFYASQLAQR 1491.77
IQEILAQVR
1069.64

%by Mass

Position

%byAA’s

2.29
1.76
1.23
1.74
1.42
1.49
1.75
1.06
1.48
2.19
1.85
1.48
1.26
2.28
2.28
1.64

24 - 36
27 - 36
53 - 60
67 - 76
201 - 208
282 - 289
290 - 299
446 - 452
453 - 462
465 - 477
486 - 495
488 - 495
506 - 513
538 - 550
551 - 563
565 - 573

2.19
1.69
1.35
1.69
1.35
1.35
1.69
1.18
1.69
2.19
1.69
1.35
1.35
2.19
2.19
1.52

Protein Coverage
By Mass

13475.2

% by Mass

20.62

By Position

122

% by AA’s

20.57
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Figure 3.8.3- Sequence of Vg1 RNA binding protein variant A Sequnce is
downloaded from http://www.expasy.org/sprot/ and sequences in red are the ones
analyzed by mass spectrometry to sequence the peptide and identify the protein band # 9a

Vg1 RNA binding protein variant A
gi|2801766|gb|AAB97457.1| KH domain-containing transcription factor B3 [Xenopus
laevis] gi|3172447|gb|AAC18597.1| Vg1 RNA binding protein variant A [Xenopus
laevis] gi|35505483|gb|AAH57700.1| MGC68429

MNKLYIGNLSENVSPPDLESLFKESKIPFTGQFLVKSGYAFVDCPDETWAMK
AIDTLSGKVELHGKVIEVEHSVPKRQRSRKLQIRNIPPHLQWEVLDSLLAQ
YGTVENCEQVNTDSETAVVNVTYANKEHARQGLEKLNGYQLENYSLKVTYIPD
EMATPQSPSQQLQQPQQQHPQGRRGFGQRGPARQGSPGAAARPKPQSEVPLRML
VPTQFVGAIIGKEGATIRNITKQTQSKIDIHRKENAGAAEKPITIHSTPEGCSAACKI
IMEIMQKEAQDTKFTEEIPLKILAHNNFVGRLIGKEGRNLKKIEQDTDTKIT
ISPLQDLTLYNPERTITVKGSIETCAKAEEEVMKKIRESYENDIAAMNLQAHLIPGL
NLNALGLFPPSSSGMPPPSAGVSSPTTSASYPPFGQQPESETVHLFIPALAVGAIIGK
QGQHIKQLSRFAGASIKIAPAEGPDAKLRMVIITGPPEAQFKAQGRIYGK
LKEENFFGPKEEVKLEAHIKVPSYAAGRVIGKGGKTVNELQNLTSAEVVVP
RDQTPDENDQVVVKITGHFYASQLAQRKIQEILAQVRRQQQQQQKT
AQSGQPQPRRK
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Figure 3.8.2.showed all the peaks of the peptide fragment ions obtained from a peptide
ITGHFYASQLAQR of Vg1RBP. The mass data given in the table 3.8.1 for the spectrum of peptide provides the sequence and molecular masses of the fragment ions. These
overlapping fragment ions were aligned on the basis of their masses to identify the
sequence of the peptide. All these operations were carried out by software programmed to
operate mass spectroscopy instrument, Bioworks software was used for Finnigan LCQ in
this study. Table 3.8.2 one of the outputs of this program that summarizes the number of
peptides sequenced for one protein and protein coverage (by the portions of protein sequenced) percentages by mass and number of amino acids for protein identification. The
sequenced peptides were then matched against one or more databases, and the protein
with highest hits (matching the most peptides) in Xenopus laevis database with Xcorr >
2.5 was selected. The Xcorr >2.5 is the value used to determine efficacy of match [111].
The Figure 3.8.2 shows the sequence of the identified protein that was downloaded from
http://www.expasy.org/sprot/. Figure 3.8.2 shows some portions of sequence highlighted in red were the sequenced peptides used in the protein identification.
The seven mass-analyzed protein bands were identified as following: Band # 3 as
Zygote arrest 1 protein, Band # 4 as an oocyte specific form of elongation factor-1 alpha
(42Sp50/thesaurin a), Bands # 7, 8a and 8b as Cytoplasmic mRNA binding protein p54 (y
box factor homolog), Band # 9a as Vg1 RNA binding protein variant A, and Band # 10 as
poly (A) binding protein. One peptide out of the protein bands around 50 kDa was identified as Xp54, RNA helicase with very high Xcorr. Most probably, the signals of other
peptides of this protein might be lost or submerged among the strong signals of peptides
from other proteins during mass analysis. The identified proteins are well characterized
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proteins of Xenopus laevis oocytes. However, none of these proteins have previously
been shown to be modified with O-GlcNAc. As oocyte specific proteins, they have been
shown to play significant roles in the regulation of translation or intracellular mRNA
translocation during the oogenesis. While, one of the proteins has been shown to play an
important role in the oocyte-to-embryo transition.
Zygote arrest 1 (Zar1), protein band # 3 is an ovary-specific maternal factor that
plays an important role during the transition of oocyte to embryo [115]. This 34 kDa
protein is 295 amino acids long and found in multiple tissues including lung, muscle and
ovary. Zar 1 mRNA is specifically synthesized in oocytes. Zar 1, localized predominantly
in cytoplasm of oocytes, rapidly disappears at the two-cell stage of embryogenesis, suggesting a critical role in the oocyte-to-embryo transition [116]. Presence of an atypical
eight cysteine Plant Homeo Domain (PHD) motif at C-terminus, suggests that the protein
might act as a translational activator, repressor or cofactor, and/ or form complexes that
modulate chromatin. In addition, Zar 1 is found to be essential for female fertility in mice
[116]. The gradual disappearance of O-GlcNAc of protein or reduction in their levels
suggests a role for O-GlcNAc in regulating the function of this protein.
Thesaurin a (42Sp50), the protein band # 4 was the first to be identified, and is
homologous to eukaryotic EF-1 α and prokaryotic EF-Tu that recruits aminoacyl tRNA to
the A-site of ribosome [117]. There are three forms of elongation factor-1 α in Xenopus
laevis, two of them are oocyte specific forms, Thesaurin a and EF-1 α and third one is
somatic form implying its absence in the oocyte, and present in embryo and adult cells
only. Thesaurin a, consistent with our identification, is an early oocyte form, and unlike
the other oocyte specific EF-1 α O, thesaurin a is exclusively and abundantly found in
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previtellogenic oocytes (stage I, II and III) of Xenopus laevis [117]. In addition, thesaurin
a is uniformly distributed throughout the cytoplasm with a one-order of magnitude lower
activity than that of the EF-1 α O that is concentrated in the mitochondrial mass (Balbiani
body) [117].
Thesaurin a is a major component of the 42S ribonucleoprotein (RNP) particle
that in addition includes of thesaurin b (40 kDa protein), tRNA, and 5S RNA. [117] The
main function of the 42S particle in oocytes is long-term storage of tRNA and 5S RNA.
Thesaurin a show specific binding to tRNA, whereas thesaurin b specifically binds to 5S
RNA. Even though, thesaurin a binds to tRNA, GTP and GDP like EF-1 α O, it has relatively low affinity for these ligands and low tRNA transfer activity. However, inspite of
its low activity, the thesaurin a can presumably function as a substitute for EF-I α due to
its high concentration in previtellogenic oocytes. Theusarin a differs from EF-1 α by its
binding properties. Thesaurin a binds more strongly to GTP than GDP, and charged
tRNA than uncharged tRNA, whereas the opposite is the case for EF-1 α. Since thesaurin
a does not binds GDP weakly, the replacement of GDP can occur in the absence of the
GDP/GTP exchange factor, EF-1 βγ. Thus, 42S particle containing thesaurin a can fully
function as a substitute for both EF-1 α and EF-1 βγ in the previtellogenic oocytes, that is
replaced by the EF-1 α O at the beginning of vitellogenesis, and which in turn is replaced
by the somatic form of EF-1 α at the beginning of the embryogenesis [117] However, the
presence of thesaurin a only in the earlier stages of oogenesis and its existence as a main
component of the 42S particle with one order of magnitude low tRNA transfer activity
also suggests the major function of thesaurin a is to store tRNA for later use during oogenesis and perhaps, early embryogenesis.
79

Even though, phosphorylation has not yet been demonstrated in thesaurin a, a
genetically distant related form of EF-1 α from rabbit reticulocytes was reported to be
phosphorylated [118]. Interestingly, this protein when phosphorylated dissociates from
complexes of mono- and polyribosomes thus affecting the rate of polypeptide chain
elongation, suggesting a regulatory role in translation for this post-translational modification. In another study, EF-1 α was immunoprecipitated with CTD110.6 antibody from
rat liver extract suggesting that it might be O-GlcNAc modified or associated with proteins that are modified [119]. Now that thesaurin a has been identified as an O-GlcNAc
containing protein, the role of this modification can be investigated. It is partially attracttive to speculate that the disappearance of thesaurin a at the beginning of vitellogenesis,
might be due to the removal of O-GlcNAc group from the protein, and thus, may lead to
its proteasomal degradation as reported in the case of transcription factor, Sp1 [91].
While tRNA and 5SRNA stored along with thesaurin in complexes referred as
thesaurisomes, oocyte maternal mRNA storage is also stored in a nontranslated ribonucleoprotein (RNP) complexes for the rapid translational recruitment during embryonic
development, after mid-blastula stage [120]. The protein bands # 7, 8a and 8b were identified as Cytoplasmic mRNA binding protein p54, y box factor homolog is one of the nonribosomal proteins associated with mRNAs in the RNP complexes. It can inhibit translation in vitro, and also has been considered as a putative translational regulator in vivo.
This protein is found in two states in cells, a heterodimer form with p56 (another y-box
factor) found free in cytoplasm or complex form with ribonucleoprotein particles. By
stage II of oogenesis, the highest concentration of p54 is achieved and the levels of the
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proteins were maintained throughout oogenesis and into early embryogenesis, but after
gastrulation it is no longer found in soluble form.
This p54 is a basic protein with a high content of arginine residues (11%) with
predicted to pI > 9 that is very near to our experimental value of pI 8.7. The protein’s
RNA binding site containing four arginine rich “basic/ aromatic islands” that are similar
to the RNA-binding domain of bacteriophage mRNA antiterminator proteins and tat protein of human immunodeficiency virus [120]. In addition, the C terminal domain of the
protein is homologous to the small E. coli cold-shock proteins These proteins are highly
expressed at very low temperature and may protect the cells from damage due to freezing, by inhibiting translational initiation. By inference, from the cold shock proteins, the
p54 may be involved in the partial blocking of translational initiation processes in an
adaptive measure to store the untranslated mRNA for later use in early embryogenesis.
In addition, the in-vitro studies have demonstrated that phosphorylation activates RNA
binding [120]. The maintenance of p54 levels thoroughout the oogenesis in contrast to
our observations where O-GlcNAc modified p54 is reduced might be due to the deglycosylation of these proteins in the later stages. Alternately, since our observations are
based on the changes per unit mass, if total amount of protein is fixed while the oocyte
enlarges and accumulates other proteins its relative amount would be reduced. Since the
protein bands # 8a and 8b were also identified as y-box factor homolog, p54 suggests that
the protein has different pI. This pI difference might be due to the different levels of
phosphorylation of this protein. Highly phosphorylated protein is more acidic than less
phosphorylated forms. Thereby, indicating that O-phosphorylation might be alternating
with O-GlcNAcylation in this proteins.
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Similar to y-box proteins, Xp54 (ATP dependent RNA helicase p54) is abundant
and an integral component of stored mRNP particles [121]. This protein belongs to the
family of DEAD-box RNA helicases that regulate RNA secondary structure in translation
initiation, splicing and ribosome biosynthesis. It possesses ATP-dependent RNA helicase
activity [121] High levels of Xp54 are expressed during early oogenesis, and are totally
missing in adult tissue. Earlier studies suggested that the Xp54 might represent expression of an oocyte specific gene. High levels of Xp54 transcripts in small oocytes correlates to maximum production of stored mRNP particles, the levels is later on reduced may
reflect relatively its low net production of mRNP particles in later stages of oogenesis and
embryogenesis. Xp54 has multiple potential Caesin kinase 2 phosphorylation sites, with
four out of five of these sites located near the C-terminus. It has been suggested the helicase activity might be regulated in two possible ways. One is by the addition or removal
of phosphate groups, and the other by the availability of cofactor at appropriate stages of
development. Since levels of Xp54 maximal remains fairly constant throughout ogenesis
up to blastula, the decrease O-GlcNAc form seen in the stages suggests deglycosylation
of the protein during the oogenesis.
In addition to the above proteins involved in storage of the tRNA and mRNA, the
band # 9a was identified as an O-GlcNAc modified protein, Vg1 RNA binding protein
(RBP) variant A. This protein associates Vg1RNA to the microtubules in order to translocate the RNA to the vegetal cortex [122] is identified as the O-GlcNAc modified proteins. The translocation of Vg1RNA requires intact microtubules and a 3’ untranslated
region (UTR) cis-acting element (termed vegetal localization element, VLE). This
Vg1RBP has five domains, four K homology (KH) and one RNA recognition motif
82

(RRM) domains. The KH domains of Xenopus Vg1RBP appeared to mediate cytoplasmic
trafficking, RNA binding and self association to homodimer [122]. However, the RRM
does not have any role in the above mentioned processes although the sequence suggests
potential for RNA binding [123]. This protein specifically binds to the VLE and is homologous to the micro-filament-binding zipcode binding protein (ZBP-1) that is involved in
β-actin mRNA localization. The Vg1RBP appears to bind independently at two distinct
sites in the VLE, and these binding sites represent a cis-acting element required for localization via the microtubule dependent pathway that oocurs in late stage III-early IV
oocytes. Interestingly, O-GlcNAc modified protein disappears during the stage progresssion, indicating the modification may have some role to play in activating the protein
after previtellogenesis (at stage III), perhaps through modulation of protein-protein
associations.
The protein band # 10 has been identified as Poly (A) binding protein (PABP).
This cytoplasmic 71 kDa protein is 633 amino acid long, binds to Poly (A) tail of adenylated mRNA and acts as positive regulator of translation [124]. PABP contains four RNA
recognition motif (RRM) domains, three of which can act independently of each other in
RNA binding, whereas the fourth one in the N-terminal region shows no detectable RNA
binding activity [125]. Even though, Western blot analyses did not detect the Poly (A)
binding proteins in oocytes or early embryos, but whole mount immunocytochemistry of
oocytes (unpublished data) and direct analysis of oocyte messenger ribonucleoprotein
particles [126] reveal the presence of this protein. Overall, these Northern and Western
analyses suggests that the expression of PABP is not constitutive, but is instead
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modulated in oocytes and the developing embryos [124]. This protein is localized in the
cell types and subcellular domains that are most active in protein synthesis [124].
In immature oocytes, the cytoplasmic polyadenylation element (CPE) in 3’
untranslated region (UTR) of maternal mRNA is bound by CPEB, which in turn bound
by Maskin, which in turn bound by eIF4E [127, 128]. The progesterone stimulation induces CPEB phosphorylation and polyadenylation. Polyadenylation, through PABP
destabilizes the Maskin-eIF4E complex, and leads to the binding of eIF4G with eIF4E
that stimulates translation. Interestingly, the cyclin B which associates with protein kinase cdk1 to form MPF in Xenopus oocytes was found to be translated by this polyadenylation binding (PAB)-mediated stimulation [128]. Thus, the protein involved in the regulation of cyclin B1 mRNA translation that is essential for the embryonic cell cycle [128].
Since these cytosolic proteins are found in association with RNA and/ or other
proteins, the characteristics of the proteins in these high molecular weight particles likely
explains all the difficulties encountered during the initial purification attempt. Immunoaffinity and affinity methods depend on the availability of O-GlcNAc binding sites on the
proteins. These sites may not be accessible in the particles due to steric constraints in the
native associated state. Thus, explaining the low yields from these technologies. However, the presence of these proteins in the high molecular weight complexes provided an
opportunity to both enrich samples with O-GlcNAc modified proteins and achieve high
yields using differential sedimentation centrifugation. The complex formation had no
effect on the ability to detect the O-GlcNAc modification by immunoblotting. Since this
technique involves SDS-PAGE analysis prior to blotting. The denaturation of the com-
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plexes during this process makes the O-GlcNAc available for antibody interaction and
thus detection.
Apart from the proteins isolated thus far, there are some neutral proteins that need
to isolated and identified in order to get the overall picture of the oocyte proteins showing
the changes in their levels or the O-GlcNAc levels during the stage progression. In addition to the proteins associated to high molecular weight particles, there are a few soluble
proteins left behind in the supernatant-100. These proteins which also show changes in
the O-GlcNAc levels during oocyte development might play an important role in regulating the cellular processes of the oocyte. Since these proteins constitute a small percentage of total oocyte proteins, they need to be enriched by WGA affinity chromatography
at low salt conditions, and later resolved by 2D-gel electrophoresis for protein sequencing
and identification.
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Chapter Four
Conclusion
The proteins that are identified thus far are among the most abundant, O-GlcNAc
modified cytosolic proteins of Xenopus laevis oocytes (stage I) and largely basic in
nature. Thesaurin a, y-box factor homolog, and Xp 54 (ATP dependent RNA helicase
p54) that store tRNA and mRNA respectively as the ribonucleoprotein (RNP) complexes
are found in maximum levels at early oogenesis. In addition, thesaurin a is an oocyte
specific EF-1 α form that is present only in previtellogenic oocytes. Earlier studies have
characterized these oocytes proteins as regulators of protein translation or as masking
(repressing translation) proteins for mRNA or as involved in RNA translocation during
oogenesis. The regulation of translation is crucial during the oogenesis, since the oocytes
store mRNA and tRNA for the post-fertilization series of cell divisions until mid-blastula,
a period where transcription is severely limited. In the same manner, the intracellular
mRNA localization that leads to asymmetric protein synthesis is necessary for the pattern
formation during early embryogenesis.
Interestingly, the zygote arrest 1 that is ovary specific protein has been suggested
to play a critical role during the oocyte-to-embryo transition. Additionally, the presence
of PHD motif also indicate a possible role as transcriptional activator, repressor or cofactors that are essential during the developmental process. On the other hand, the Poly (A)
binding protein has a role in initiating the protein translation. Importantly, the cyclin B1
mRNA of Xenopus oocytes was shown to be translated by this polyadenylation binding.
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Thus, indicating a role in regulating the cell cycle. To summarize, all the identified
proteins play crucial roles in the developmental process, and the changes in the OGlcNAc levels might be modulating their activities like the O-phosphorylation.
Finally, the high content of arginine residues in these proteins explains their basic
nature, and these arginine rich regions facilitate the possible interactions with RNA. The
O-GlcNAc on the proteins involved in the packaging, translocation and translation of
RNA suggest that O-GlcNAc may play a role in the modulating the interactions. In addition, the sudden disappearance of O-GlcNAc modified thesaurin a that is at the stage III
of oogenesis might be due to the deglycosylation leading to proteosomal degradation.
Therefore, in order to understand the putative role of O-GlcNAc modification on this
oocyte specific proteins, these proteins need to further studied. In addition, there are some
more modified oocyte proteins that needs to be identified in order understand the significance of these proteins and the potential function of O-GlcNAc in the developmental
process of oocyte. The findings of this investigation could be a significant contribution to
the biochemistry of oocyte development and more generally to O-GlcNAc mediated cellular processes. In addition, it adds several more proteins to the growing list of O-GlcNAc
modified proteins.
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Appendix A: Abbreviations
O-GlcNAc

N-acetylglucosamine attached to a serine or threonine

GlcNAc

N-acetylglucosamine

O-GlcNAcase

N-acetyl-β-glucosaminidase

mRNA

Messenger RNA

DNA

Deoxy ribonucleic acid

GVBD

Germinal vesicle breakdown

tRNA

Transfer RNA

snRNA

Small nuclear RNA

rGTP

Guanosine triphosphate

dTTP

Deoxyribothymidine 5’ –triphosphate

UDP-glucose

Uridine Diphosphoglucose

HSP

Heat shock protein

OGT

O-GlcNAc Transferase

PUGNAc

O-2-acetamido-2-deoxy-D-glucopranosylidene

STZ

Streptozotocin

WGA

Wheat germ agglutinin

GFAT

Glutamine: Fructose-6-phosphate amidotranferase

DON

6-diazo-5-oxonorleucine

OR-2

Oocyte ringers buffer 2

HEPES

4-2-hydroxymethyl-1-piperazine ethanesulfonic acid

BSA

Bovine serum albumin

Tris

Tris-hydroxymethyl-aminomethane
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IgG

Immunoglobulin type G

IgM

Immunoglobulin type M

UDP

Uridine diphosphate

SDS

Sodium dodecyl sulfate

PAGE

Polyacrylamide gel electrophoresis

TEMED

N, N, N’, N’-tetra-methyl-ethylenediamine

PVDF

Polyvinyl difluoride

PBS

Phosphate buffer saline

RL-2

Monoclonal Antibody against O-GlcNAc

CDT110.6

Monoclonal Antibody against O-GlcNAc

PBST

Phosphate buffered saline with Tween 20

HSPBS

High salt phosphate buffered saline with Tween 20

CTD

C-terminal domain

TBST

Tris buffered saline with Tween 20

TBS-HT

Tris buffered saline with high Tween 20

TBS-D

Tris buffered saline with high detergent

DAB

Diaminobenzidine

ATP

Adenosine triphosphate

Glc

Glucose

Gal

Galaactose

PMSF

Phenylmethyl-sulfonyl fluoride

EDTA

Ethylene-diamine tetracetic acid

HRP

Horse radish peroxidase
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1D-gel

One-dimensional gel

2D-gel

Two-dimensional gel

RIPA

Radioimmunoprecipitation assay

IPG

Immobilized pH gradient

IEF

Isoelectric focusing

NL

Non-linear

DTT

Dithiothretol

CHAPS

3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate

MS 222

Tricaine methyl sulfonate

PSM

Protein solubilizing mixture

RBP

RNA binding protein

Vg 1 RBP

Vegetal 1 RNA binding protein

VLE

Vetegal localization element

EF-1 α

Elongation factor-1 alpha

RNP

Ribonucleoparticle

EF-1 α O

Elongation factor alpha (oocyte specific form)

CK 2

Casein kinase 2

UTR

Untranslated region

KH

K Homolog

ZBP-1

Zipcode binding protein

HBP

Hexosamine biosynthetic pathway

Zar 1

Zygote arrest 1

Xp54

ATP dependent RNA helicase p54
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PABP

Poly (A) binding protein

CPE

Cytoplasmic polyadenylation element

CPEB

Cytoplasmic polyadenylation element binding protein

eIF

Elongation initiation factor

pI

Isoelectric point
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Appendix B: Structures of some of the discussed and used sugars and inhibitors

Glucose

Glucosamine

N-Acetylglucosamine

Galactose
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Guanosine 5’-triphosphate

Uridine diphosphate-N-acetylglucosamine
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Inhibitors

Streptozotocin

6-Diazo-oxonorleucine

PUGNAc
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Appendix C: Mass data analysis of Thesaurin a, p54 (y-box factor homolog),
Xp54 RNA helicase, Zygote arrest 1 and Poly (A) binding protein
Figure 1-Mass spectrum of a peptide of Elongation factor (Thesaurin a)(42Sp50)
Elongation factor 1-alpha (EF-1-alpha) (42Sp50)
gi|416929|sp|P17506|EF11_XENLA Elongation factor 1-alpha (EF-1-alpha) (42Sp50) (Thesaurin A) gi|64489|emb|CAA79605.1| 42Sp50 [Xenopus laevis]

MTDKAPQKTHLNIVIIGHVDSGKSTTTGHLIYKCGGFDPRALEKVEAAAAQLGKSSFKFAWILDKLKAERERGITIDISLWKFQTNRFTITIIDAPGHRDFIKN
MITGTSQADVALLVVSAATGEFEAGVSRNGQTREHALLAYTMGVKQLIVCVNKMDLTDPPYSHKRFDEVVRNVMVYLKKIGYNPATIPFVPVSGWTGENISSPS
QKMGWFKGWKVKRKDGFTKGQSLLEVLDALVPPVRPANKPLRLPLQDVYKIGGIGTVPVGKIETGILKPGMTISFAPSGFSAEVKSIEMHHEPLQMAFPGFNIGFN
VKNIAVKSLKRGNVAGNSKSDPPTEASSFTAQVIILNHPGFIKAGYSPVIDCHTAHITCQFAELQEKIDRRTGKKLEDNPGLLKSGDAAIITLKPIKPFCVERFFDYPP
LGRFAARDLKQTVAVGVVKSVEHKAGAAARRQVQKPVLVK

Sequence

MH+

% by Mass

Position

% by AA’s

VEAAAAQLGK

957.54

1.89

45 - 54

2.16

FTITIIDAPGHR

1340.73

2.65

88 - 99

2.59

RFDEVVR

920.50

1.82

169 - 175

1.51

FDEVVR

764.39

1.51

170 - 175

1.30

IGGIGTVPVGK

997.60

1.97

259 - 269

2.38

KLEDNPGLLK

1126.65

2.22

389 - 398

2.16

FFDYPPLGR

1111.56

2.19

418 - 426

1.94

Protein coverage Totals
By mass

6359.5

% by mass

12.56

By position

59

% by AA’s

12.74
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Figure 2- Mass data analysis of a peptide Xp54, RNA Helicase (only one peptide was
found with High Xcorr).

#1753-1753 RT:68.05-68.05 NL: 6.63E5
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Figure 3- Mass data analysis of a peptide of p54, y-box factor homolog

MSSEVETQQQQPDALEGKAGQEPAATVGDKKVIATKVLGTVKWFNVRNGYGFINRNDTKEDVFVHQTAIKKNNPRKYLRSVGDGETVEFDVVEGEKGAEAANVT
GPEGVPVQGSKYAADRNHYRRYPRRRGPPRNYQQNYQNNESGEKAEENESAPEGDDSNQQRPYHRRRFPPYYTRRPYGRRPQYSNAPVQGEEAEGADSQGTDEQG
RPARQNMYRGFRPRFRRGPPRQRQPREEGNEEDKENQGDETQSQPPPQRRYRRNFNYRRRRPENPKSQDGKETKAAETSAENTSTPEAEQGGAE
Sequence
MSSEVETQQQQPDALEGK
EDVFVHQTAIK1286.67
SVGDGETVEFDVVEGEK
FPPYYTRRPYGR

AA
S
V
G
D
G
E
T
V
E
F
D
V
V
E
G
E
K

MH+
2004.92
3.72
1795.82
1572.81

M+nH
89.05
188.12
245.14
360.16
417.19
546.23
647.28
746.34
875.39
1022.46
1137.48
1236.55
1335.62
1464.66
1521.68
1650.73
1778.82

% by Mass
5.79
60 - 70
5.19
4.54

A
60.04
159.11
216.13
331.16
388.18
517.23
618.27
717.34
846.38
993.45
1108.48
1207.55
1306.62
1435.66
1492.68
1621.72
1749.82

Position
1 - 18
3.63
80 - 96
172 - 183

A*
43.02
142.09
199.11
314.14
371.16
500.20
601.25
700.32
829.36
976.43
1091.45
1190.52
1289.59
1418.63
1475.65
1604.70
1732.79

Ao
42.03
141.10
198.12
313.15
370.17
499.22
600.26
699.33
828.37
975.44
1090.47
1189.54
1288.61
1417.65
1474.67
1603.71
1731.81

% by AA’s
5.94
5.61
3.96

B
88.04
187.11
244.13
359.16
416.18
545.22
646.27
745.34
874.38
1021.45
1136.47
1235.54
1334.61
1463.65
1520.68
1649.72
1777.81

B*
71.01
170.08
227.10
342.13
399.15
528.19
629.24
728.31
857.35
1004.42
1119.45
1218.52
1317.59
1446.63
1503.65
1632.69
1760.79

Bo
70.03
169.10
226.12
341.15
398.17
527.21
628.26
727.33
856.37
1003.44
1118.46
1217.53
1316.60
1445.64
1502.67
1631.71
1759.80

C

X

Y
1795.82
1708.79
1609.72
1552.70
1437.67
1380.65
1251.61
1150.56
1051.49
922.45
775.38
660.36
561.29
462.22
333.18
276.16
147.11

Y*
1778.80
1691.77
1592.70
1535.68
1420.65
1363.63
1234.58
1133.54
1034.47
905.43
758.36
643.33
544.26
445.19
316.15
259.13
130.09
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1777.81
1690.78
1591.71
1534.69
1419.66
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1233.60
1132.55
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757.37
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543.28
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Figure 4- Mass data analysis of a peptide of Zygote arrest 1, Zar 1
Sequence of Zar 1
MYPAYNPYSYRYLNPRNKGMSWRQKNYLASYGDTGDYCDNYQRAQLKAILSQVNPNLTPR
LCRANTRDVGVQVNPRQDASVQCSLGPRTLLRRRPGALRKPPPEQGSPASPTKTVRFPRT
IAVYSPVAAGRLAPFQDEGVNLEEKGEAVRSEGSEGGRQEGKQGDGEIKEQMKMDKTDEE
EAAPAQTRPKFQFLEQKYGYYHCKDCNIRWESAYVWCVQETNKVYFKQFCRTCQKSYNPY
RVEDIMCQSCKQTRCACPVKLRHVDPKRPHRQDLCGRCKGKRLSCDSTFSFKYII

AA

M+nH

A

A*

Ao

B

B*

Bo

Y

Y*

Yo
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73.05
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55.02
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I
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1333.76
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252.21
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1238.69
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S
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385.25
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Q

514.31
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1038.57
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Figure 4- Mass data analysis of a peptide of Ploy (A) binding protein (PABP)
Sequence of PABP
QPADAERALDTMNFDVIKGRPVRIMWSQRDPSLRKSGVGNIFIKNLDKSIDNKALYDTFS
AFGNILSCKVVCDENGSKGYGFVHFETQEAAERAIDKMNGMLLNDRKVFVGRFKSRKERE
AELGARAKEFTNVYIKNFGDDMNDERLKEMFGKYGPALSVKVMTDDNGKSKGFGFVSFER
HEDAQKAVDEMYGKDMNGKSMFVGRAQKKVERQTELKRKFEQMNQDRITRYQGVNLYVKN
LDDGIDDERLRKEFLPFGTITSAKVMMEGGRSKGFGFVCFSSPEEATKAVTEMNGRIVAT
KPLYVALAQRKEERQAHLTNQYMQRMASVRVPNPVINPYQPPPSSYFMAAIPPAQNRAAY
YPPGQIAQLRPSPRWTAQGARPHPFQNMPGAIRPTAPRPPTFSTMRPASNQVPRVMSAQR
VANTSTQTMGPRPTTAAAAAASAVRAVPQYKYAAGVRNQQHLNTQPQVAMQQPAVHVQGQ
EPLTASMLAAAPPQEQKQMLGERLFPLIQAMHPTLAGKITGMLLEIDNSELLHMLESPES
LRLKVDEAVAVLQAHQAKEAAQKVVNATGV PTA

M+nH
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Ao

B
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Bo

Y

Y*

Yo

130.07

101.07

84.05

83.06

129.07
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1389.67
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201.11

172.11
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182.09

1261.61
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319.15

1190.57

1173.55
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1035.50
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404.24

450.25

433.22
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1053.52

1036.49

552.30

523.30
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551.29
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940.43

923.40

922.42

666.34
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619.33
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648.31

647.33

839.38

822.36

821.37

794.40

765.40

748.37

747.39

793.40

776.37

775.39

725.34

708.31
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957.47

928.46

911.44

910.45

956.46

939.43

938.45

597.28

580.26

579.27

1088.51

1059.50

1042.48

1041.49

1087.50

1070.47

1069.49

434.22

417.19

416.21

1216.57

1187.56

1170.54

1169.55

1215.56

1198.53

1197.55

303.18

286.15

285.17

1372.67

1343.66

1326.64
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1353.65
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158.09

157.11
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